-i-
Pharmaceutical
Applications of Eukaryotic Microalgae
Angeliki Tsianta SCHOOL OF ECONOMICS, BUSINESS ADMINISTRATION & LEGAL STUDIES A thesis submitted for the degree of Master of Science (MSc) in Bioeconomy: Biotechnology and Law
December, 2019 Thessaloniki – Greece
-ii-
Student Name: Angeliki Tsianta
SID: 4402180006.
Supervisor: Dr. Savvas Genitsaris I hereby declare that the work submitted is mine and that where I have made use of another person’s work, I have attributed the source(s) according to the Regulations set in the Student’s Handbook.
December 2019
Thessaloniki - Greece
-iii-
Abstract
This dissertation was written as a part of my MSc in Bioeconomy: Biotechnology and
Law at the International Hellenic University.
The first section of this study deals with the applications of microalgae in the
pharmaceutical sector. Eukaryotic microalgae are photoautotrophic micro-organisms
and constitute the foundation of most aquatic environments due to their rich
biodiversity and possibly high growth efficiency; nevertheless, they represent a vast and
underexplored bioresource. About the safety and the prevention of diseases,
microalgae have been reported as potential sources of new natural antimicrobials. Such
species develop various secondary bioactive metabolites with antibacterial activities
such as free saturated or unsaturated fatty acids, carbohydrates, proteins, and lipids,
and work is underway to find natural molecules to restrict the misuse of industrial
antibiotics. Therefore, microalgae consist of one major promising commercial
opportunity for these substances in the field of pharmaceuticals, antibiotics, anticancer,
antibacterial, antiviral, anti-fungal functions, and the treatment of other human
diseases.
The second part includes a SWOT analysis of a start-up pharmaceutical company using
microalgae, with emphasis on European regulations for new bioproducts, as well as
initiatives for public and private funding. The pharmaceutical industry has had an
accelerating rate of costs increase in new drug production while the number of new
drugs authorized and released in the market has been very small due to increased
public regulation. Partnership with the biotechnology industry is one of the key choices
to improve this situation. If the pharmaceutical industry succeeds in addressing the
issues responsible for high cost in the sector with a new marketing strategy, it might
prove very beneficial for both of them as a partner of the biotechnology industry.
Finally, this sustainable business model for a start-up pharmaceutical company is
recommended in accordance with European strategies for a sustainable Bioeconomy.
Keywords: Microalgae; Pharmaceutical applications; European regulations; Business
model
-iv-
Acknowledgements
This thesis could not be carried out without valuable suggestions and support in the
context of planning and research progress from my supervisor Dr. Savvas Genitsaris,
who I am extremely thankful for his contribution and mentoring throughout the Master
program and in every area of my education at the International Hellenic University.
I would finally like to express my thanks, love, and respect to my family and my
husband for their tolerance and support for my projects.
Angeliki Tsianta 31st December 2019
1
Contents Abstract .................................................................................................................................................... iii Acknowledgements ............................................................................................................................. iv 1. Introduction ....................................................................................................................................... 2
1.1. General Characteristics of Microalgae ............................................................................. 2 1.2. Microalgae as Organisms with Particular Biotechnological Interest................... 3 1.3. Macromolecules of microalgae useful for pharmaceutical applications ............ 5 1.4. Aim of the study........................................................................................................................ 7
2. Methodology ...................................................................................................................................... 9 2.1. Results .......................................................................................................................................... 9
3. Pharmaceutical uses of microalgae ........................................................................................ 12 3.1. Anticancer activity ................................................................................................................ 12 3.2. Antiviral activity .................................................................................................................... 16 3.3. Antibacterial activity ........................................................................................................... 20 3.4. Antifungal activity ................................................................................................................ 23 3.5. Potential of Microalgae in Cardiovascular Disease Prevention .......................... 26 3.6. Metabolism .............................................................................................................................. 30 3.7. Respiratory .............................................................................................................................. 31 3.8. Inflammation-Oxidative Stress-Allergies .................................................................... 31 3.9. Immunology (various & infectious diseases) ............................................................. 33 3.10 Hepatology ............................................................................................................................. 35 3.11 Dermatology .......................................................................................................................... 36 3.12 Neuroscience......................................................................................................................... 39 3.13 Ophthalmology ..................................................................................................................... 40
4. European Regulations concerning Microalgae .................................................................. 41 5. Swot analysis – Case study of a fictional microalgae-based carotenoid production company ................................................................................................................................................ 43 6. Conclusions ...................................................................................................................................... 47 7. Future perspectives ...................................................................................................................... 49 Bibliography......................................................................................................................................... 50
2
1. Introduction
1.1. General Characteristics of Microalgae
Certainly, “our life depends on microalgae” since they compose 50 percent of overall
oxygen production (Chapman, 2013). As autotrophs support aquatic ecosystems, and in
general all land plants and animals lean on microalgae directly or indirectly. Firstly, the
primary production of marine and freshwater bodies relies on microalgae (Borowitzka
et al, 2016). Secondly, they are situated in the base of food chains having an essential
role in the world’s aquaculture industries for their protein needs (Griffiths, 2013).
Based on the size and morphology, algae may be subdivided into 2 main categories:
macroalgae and microalgae. Macroalgae are composed of multiple cells, organized into
structures that resemble higher plant roots, stems, and leaves (e.g. kelp). Microalgae
are mostly unicellular, a diverse group of primary producers (autotrophs) organisms
capable of forming organic compounds from pure inorganic materials like atmospheric
or marine carbon dioxide (Sigamari et al, 2016). They are microscopic in comparison to
algae which are simpler autotrophic organisms with a large variety (Ranganathan and
Yaakob, 2013). Today's advanced plant life is believed to have been developed from
these basic plant-like microscopic organisms (Mutanda, 2013).
Around 41,000 species of macroalgae and microalgae were described. The
microalgae are categorized according to the quality of photosynthetic pigments, the
food reserve for carbohydrates, the cell walls, the structure and orientation of flagella
1(Levine and Fleurence, 2018). Also, the microalgae are described in the generally
accepted algae phyla (divisions), meaning:
1 A flagellum (plural: flagella) is a long, whip-like structure which allows to move certain single organisms https://simple.wikipedia.org/wiki/Flagellum.
3
Figure 1. Microalgae Divisions. Modified from: Griffiths, 2013.
Prokaryotic cyanobacteria are often included in this term as well, but some scientists
exclude the prokaryotic blue-green algae (=cyanobacteria) and limit the definition of
microalgae to include solely eukaryotic cells (Stanier et al., 1971). This thesis is
restricted to eukaryotic microalgae only.
1.2. Microalgae as Organisms with Particular Biotechnological Interest
There are several reasons why interest in microalgae growth is now thriving globally.
Micro-algae are not particularly complex micro-organisms and are present in almost all
earth's habitats from the sea, freshwater, desert sands, and hot springs, to snow and
ice (Williams & Laurens, 2010). These many different environmental niches are,
planktonic, benthic (sand, water, soil), epilithic, epiphytic, (symbiosis with the fungus
and invertebrates), aquatic and in rare occasions parasitic relationships. Other classes
of microalgae may form biofilms, colonial structures, mats and grasses.
Although the total amount of microalgae listed is vast, only a few dozen are genuinely
elucidated in their nutritional, environmental, pathogenic or business potential (Levine
and Fleurence, 2018). Additionally, only a small percentage, i.e. approximately 20
microalgae, are used economically (Posten and Chen, 2016).
Furthermore, these microalgae contain proteins, pigments, essential fatty acids,
vitamins, polysaccharides and minerals (Parsaeimehr, 2017). Such high-value products
Microalgae Divisions (phyla)
Chlorophyta (green algae)
Chrysophyta
Cryptophyta
Dinophyta (dinoflagellates)
Haptophyta (coccolithophorids)
Euglenophyta (euglenoids)
Glaucophyta
Rhodophyta (red algae)
ochrophyta (diatoms of
bacillariophyta)
4
may be proven particularly important and beneficial to the pharmaceutical industry by
giving new choices to treat illnesses like inflammation and immunomodulating actions
(Ahmadi et al, 2015). Eventually, the microalgae that provide us with oxygen, foods,
and car fuel, also provide us with effective medical substances against virus diseases
(Herpes simplex and AIDS), cancer and drug-resisting bacterial strains. Pharmaceutical
products of quality and their industrial marketing are still developed and can be viewed
as a key to a multimillion-dollar industry. Scientists have just begun to explore the huge
biological resource and physiological perspective of microalgal species as growing in
every environmental niche (Bhattacharjee, 2016).
The evolution of algae over 2,500 million years, its abundance and ability to
withstand extreme environments have contributed to novel strategies of protection,
interaction, and survival, leading to their human drug and nutraceutical potential.
Nevertheless, one cautionary note is that the discovery of drugs in microalgae depends
on environmental regimes that induce metabolic plasticity (Lauritano et al., 2016). The
rates of metabolites and bioactivity depend on habitat and seasonal conditions.
Production and concentration of primary and secondary metabolites are based on a
process of development (Vidoudez and Pohner, 2012), different clones (Gerecht et al.,
2011), kind of light (Depauw et al., 2012), control of temperature (Huseby et al., 2013),
media for seed (Alkhamis and Qin, 2015), weeding control procedure (Pohnert, 2002), a
technique for extraction (Juttner, 2001) and various elements (Chen et al., 2011).
The nutritional needs of some microalgal strains are recognized and microalgal
growing technology is evolving quickly. Also, the development of protocols in genetic
engineering has brought new approaches to molecular algal systems. The general study
recently carried out in genomics and molecular biology methods of microalgae have
achieved remarkable dimensions, with huge numbers of undiscovered algae strains
from extreme environments (Brodie and Lewis, 2007).
5
1.3. Macromolecules of microalgae useful for pharmaceutical applications
A large quantity of various components is produced by microalgae, such as:
Lipids
Microalgae contain a large number of lipids, around 30–50% of their total weight. In
comparison to other lipid-based crops, microalgae lipids can assemble a higher
percentage which makes them more appealing to produce biodiesel and health food
supplements (Yeh and Chang, 2012).
Proteins
Proteins are part of the main components of microalgae, representing between 50
and 70% of their composition. Besides, protein is can be consumed by humans or
animals (Chew et al., 2017). Even though some microalgae comprise toxic proteins,
testing can be carried out to discover the safe proteins for use.
Carbohydrates
Microalgae usually have a high carbohydrate amount that is around 50% greater
than their dry weight because they have good effectiveness in photo-conversion and
easy storage of carbohydrates (Yen et al., 2013). Algal carbohydrates are composed
mainly of glucose, starch, cellulose, and polysaccharide of several kinds. Microalgae
polysaccharides can regulate the immune system and inflammatory reactions, and
produce cosmetic chemicals, food ingredients, and natural therapeutic agents.
Pigments
It is important to highlight three basic natural pigment classes in microalgae:
carotenoids, chlorophyll, and phycobiliproteins. These pigments were used as vitamins
in food and feed, additives, cosmetics, pharmaceutical industries, agents to color food
and biomaterials (Nobre et al., 2013; Tamiaki et al., 2014, Zhou et al, 2015). First of all,
carotenoids are fat-soluble coloring agents, which dye plants, and secondly
chlorophylls are lipid-soluble pigments existing in vegetables and fruit during
photosynthesis. Another carotenoid from microalgae is astaxanthin, an important
6
antioxidant agent, as carotenoids have strong anti-aging, sun protection, and anti-
inflammatory impact in the immune system (Cheng et al., 2016).
Vitamins
Compared with common food, microalgae have high levels of vital vitamins, like
riboflavin a very important vitamin for maricultured animals (Brown and Farmer, 1994).
Also, more studies must be performed to test the safety of these vitamins after
consumption (Bonnet et al., 2010).
Polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFA) are commonly known as important food
elements that help prevent multiple cardiovascular diseases. The fast diminution of
marine resources has hampered the acquisition of these ingredients from ocean fish,
where augmented PUFAs demand has been responsible for the revealing of substitute
sources for EPA and DHA (fatty acids). Microalgae can produce PUFAs that are
important to human health and nutrition (Wang et al., 2015b).
These previous components may have different applications as table 1 demonstrates.
7
Table 1. Potential uses for bioproducts obtained from microalgal biorefineries. Modified from: Chew et al., 2017.
Activity Application Nutraceutical, antimicrobial, anti-
inflammatory Nutritional supplement,
antiproliferative, capacity to resist
infections and diseases Antioxidant, natural pigment Supplement and food ingredient for
humans, feeding of fish and shellfish Biofuels Fermentation of natural gas via
biomass digestion to produce biodiesel
Fertilizers Utilization of biomass in arable land for
production of nitrogen and phosphorus High-value molecules
Chlorophyll-a, phycocyanin, b-carotene,
γ-linolenic acid, eicosapentaenoic acid,
and stable biochemical isotopes
Anticancer and antitumor Antiproliferative. Inducing G1 inhibition
in post-gastric carcinoma cells Chemical industry Evaporative organic compounds
1.4. Aim of the study
The current study΄s aim is to discuss on a global scale the latest developments in
pharmaceutical research with the use of microalgae and to highlight the recent
discoveries in the field.
The study's first section attempts more explicitly to summarize their potential
pharmaceutical innovations in international literature as well as the different
applications in the areas of human health. This section discusses the understanding of
the microalgae as the origin and ingredients in bioactive molecules, i.e. in cancer
treatment, metabolism, oxidative stress, inflammation, immunology, cardiovascular-
renal-respiratory-hepatology-dermatology-neuroscience-ophthalmology, and rare
diseases and accidents which consist of basic domains in the pharma industry (www.
novartis.com).
8
The second section includes the regulations and the restrictions as far as the
pharmaceutical use of microalgae is concerned. An attempt to link the pharmaceutical
uses of microalgae with the concepts of Bioeconomy, circular economy, and
sustainability on the European Union level was made. In this chapter also, a swot
analysis of a start-up biotechnological company using microalgae is presented. Swot
analysis is essential to coordinate the different departments of the company by
defining the internal planned factors-strengths and weaknesses, and the external
planned factors-opportunities and threats. With the practical application of the above
principles, a sustainable business model is introduced which illustrates the high level of
applicability and inclusion into the EU project.
9
2. Methodology
The Elsevier Scopus and ScienceDirect databases simultaneously with Google
Scholar and PubMed were thoroughly searched by applying the following keywords
[pharmaceutical uses of microalgae, anticancer-antiviral-antibacterial – antifungal –
cardiovascular – renal – metabolism – respiratory – inflammation – immunology –
hepatology – dermatology – neuroscience -ophthalmology – rare diseases – wounds
(alone or in combination with microalgae)] in the "Article title, abstract, keywords"
section in Scopus of ScienceDirect, without any constraint of the date or report form.
From 1960 to 2019 the search provided thousands of documents. The findings have
been categorized and checked, excluding those that did not match the study criteria.
2.1. Results
This research reveals the augmentation of publications about the pharmaceutical
use of microalgae during the last 3 decades, as demonstrated in Fig.2, which follows
the growth of technologically advanced equipment and the marketing of microalgae-
based products. Especially the last decade from 2010 until 2019 the rise of publications
is spectacular:
Figure 2: Graphical representation of researches on microalgae pharmaceuticals from 1990 to
2019.
0
200
400
600
800
1000
1200
Publications
Publications
10
As far as pharmaceutical uses of microalgae are concerned, we ascertain that the publications about anticancer, antiviral, antibacterial, and
antifungal drugs from microalgae have risen especially since 2010. This is due to the growing interest in finding new substances that will defeat
various diseases. In graph 1, we observe that microalgae substances for metabolism show a big development. Moreover, pharmaceutical use of
microalgae in cardiovascular, dermatology, inflammation, and neuroscience present also, a significant rise during the last decade. On the other
hand, renal and respiratory drugs for microalgae have not been studied satisfactorily yet, as well as hepatology drugs. Finally, microalgae
research for accident wounds augments especially the last years, while publications for ophthalmology and rare diseases are also limited.
Graph 1: Publications on microalgae per human diseases from 1990 to 2019.
0
200
400
600
800
1000
1200
1400
1600
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Publications per are of interest
Anticancer Antiviral Antibacterial Antifungal Cardiovascular renal metabolism respiratory
inflammation immunology hepatology dermatology neuroscience opthalmology rare diseases wounds
11
On figures below, we see the top 15 countries in microalgae biotechnology and
research such as United States, Russia, Iran, China, Japan, Germany, India, France,
Canada, Australia, Brazil, Spain, Algeria, United Kingdom, South Korea. The United
States, Russia, and China are the three leading counties in publications.
Figure 3: World map with main countries and their number of scientific publications on
microalgae. The red-orange color indicates a greater number of publications, the blue-green color
indicates the smaller, and white when it does not exist. Modified by Garrido-Gardenas et al.,
2018.
Figure 4: Graph on publications concerning the use of microalgae in pharmaceuticals per country.
12
3. Pharmaceutical uses of microalgae
Physicochemical and pharmacological studies have given particular attention to
extracting and generating new bioactive metabolites for therapeutic purposes from
marine micro-algae. On the other hand, microalgae are a healthy source of human
dietary due to macro and micronutrients. These bioactive molecules may have the
ability to improve human health (Nazih and Bard, 2018). Hence, microalgae can be
utilized as a functional food (supplements) as well as pharmaceutical.
In this coursework, eukaryotic microalgae products are discussed in terms of
pharmaceutical use together with their use as functional food (nutraceuticals).
3.1. Anticancer activity
In 2015, cancer, worldwide the second most important cause of death, killed 8.8
million people, mainly: Cancer of the liver (788,000 deaths); cancer of the colon
(774,000 deaths); cancer of the stomach (754,000 deaths); cancer of the breast
(571,000 deaths) (OMS data). It is predicted that the number of new cases will increase
by 70% over the next two decades. Also, the increasing economic effect of cancer is
significant: in 2010, the total costs per year of the disease were projected to be around
US$ 1160 billion (US$) (Dewi et al., 2018).
Cancer is the failure or dysfunction of precisely regulated processes of a cell, such as
a cell division, proliferation, and programmed cell deaths (apoptosis), as well as the
mechanisms of controlled feedback (Klaunig and Kamendulis 2004). This contributes to
the rapid growth and metastases of the cancer cell (Abel et al. 2014).
Chemotherapy, one of the key therapies currently available, has little efficacy by some
life-threatening negative results and the formation of therapeutic resistant cell lines. The
use of natural products in the therapy of various diseases consists of a significant field of
research for new drugs. Microalgae can generate biologically active molecules for the
pharmaceutical industry because they can be conveniently grown, short-produced, and
environmentally friendly. The majority of published research on anticancer properties
from microalgal strains studied pure ingredients rather than extracts to diminish the
danger of patient side effects (Dewi et al., 2018). Bioactive microalgae molecules with
13
anticancer applications are carotenoids, glycolipids, polysaccharides, and proteins (Talero
et al., 2015).
Carotenoids and Cancer
Five carotenoids with important anti-cancer activities are reported: β-carotene,
lutein, astaxanthin, violaxanthin, and fucoxanthin. Since the majority of organisms
cannot generate these compounds, they depend on nutrition as a source.
β-carotene
Microalgae are a rich carotenoid origin (Varela et al., 2015), with Dunaliella for β-
carotene and Haematococcus for astaxanthin being the major generators. Palozza et al.
(2005) therefore, found out that the development of human colon cancer cell lines was
significantly limited by β-carotene pigments.
Astaxanthin
Haematococcus pluvialis, Chlorella zofingiensis, and Chlorococcum sp. are the major
microalgal sources of astaxanthin (Liu et al., 2014). Palozza et al. (2009) have
investigated the impact of astaxanthin on the development of cell lines and have
demonstrated the ability of this carotenoid to impede the proliferation of human CRC
(colorectal cancer) cell lines. Nonetheless, no astaxanthin clinical trials have been
published yet. The strong association between astaxanthin concentrations and
antiproliferative impact on the lines of hepatoma, breast, and pulmonary cancer has
been stated by Song et al. (2011).
Zhang et al. (2011) found that astaxanthin was the most powerful of the four types of
carotenoids to impede cell proliferation. Some studies have documented the impact of
astaxanthin on apoptosis (programmed cell death). Astaxanthin from microalgae
should, therefore, be a perfect candidate, not only for the control of cancer but also as
a chemotherapy tool. However, to prove this hypothesis, clinical research is required
(Nazih and Bard, 2018).
14
Lutein
An inverse connection between nutritional carotenoid, particularly lutein intake, and
various types of cancers (colon, lung, breast ) is generally proven (Dorgan et al., 1998).
Lutein is primarily developed by Dunaliella salina (Fu et al., 2013), Chlorella sorokinian
(Pasquet et al., 2011) and Chlorella prothelkoides (Shi and Chen, 2002), and has anti-
proliferative impact on human colon cell line HCT-116 (Cha et al., 2008). Also, low
levels of dietary lutein (0.002% and 0.02%) have been shown to prevent the occurrence
and development of mammary tumors (Park et al., 1998).
Violaxanthin
Violaxanthin isolated from D. salina (Pasquet et al., 2011) and Chlorella ellipsoidea
(Talero et al., 2015) has antigrowth and proapoptotic effects against human colon
cancer cell line HCT-116.
Fucoxanthin
Fucoxanthin is the most promising carotenoid against cancer expansion. Their anti-
proliferative results on SK-hepatoma, BNL CL.2(embryonic liver) cells, cancer cells
(Caco-2, HT29, and DLD-1), the cells of prostate cancer PC-3, and HL-60 leukemia, were
described by Kumar and al. (2013). Fucoxanthin, therefore, is demonstrating great
potential in cancer as a chemotherapeutic product.
Lipids and Cancer
Human nutrition includes low amounts of a fatty acid group, ω-3 polyunsaturated
fatty acids (ω-3 PUFAs), and high quantities of ω-6 PUFAs, which lead to cancer
incidence. PUFAs and glycolipids are known to be effective anticancer factors by
activating apoptosis and also by increasing the responsiveness of tumors to anticancer
drugs (Nazih and Bard, 2018). Fish oils are the main sources of ω-3 PUFAs. Over the last
years, microalgae have been turned into a good option for ω-3 PUFAs (DHA2, EPA3).
The fact that the high consumption of ~ 3 PUFAs, mainly DHA and EPA, minimizes the
2 Docosahexaenoic acid 3 Eicosapentaenoic acid
15
risk of breast, colon, prostate, pancreatic and endometrial cancer has been indicated
by epidemiological studies (Arem et al., 2013).
A lot of in vitro studies have presented that DHA shows anticancer activity by
provoking oxidative stress and oxidative DNA damages to cancer cells. Indeed, both
EPA and DHA cause ROS (reactive oxygen species) concentration and caspase-84-
dependent apoptosis in breast cancer, pancreatic cancer (Fukui et al., 2013; Kang et al.,
2010), and prostate cancer cells. Clinical trials have also revealed that the efficiency of
chemotherapy increases with ω 3-PUFAs, particularly DHA (Bougnoux et al., 2009).
Glycolipids, these variant lipids, are located at high amounts in thylakoid
membranes of microalgae chloroplasts. Monogalactosyldiacylglycerol (MGDG) shrunk
the HT-29 human colon adenocarcinoma tumors (Mizushina et al., 2012) and also
digalactosyldiacylglycerol (DGDG) created apoptosis in Caco-2 colon cells (Hossain et
al., 2005).
Polysaccharides and Cancer
Diatoms, chlorophytes, prasinophytes, haptophytes, rhodophytes, and dinoflagellates
(Raposo et al., 2015) produce a large number of polysaccharides. One important
anticancer substance is GA3P (d-galactan sulfate, associated with l-(+)- lactic acid), an
extracellular polysaccharide, refined from Gymnodinium sp., which hampered the
proliferation of different cancer cell lines, especially some colon cancer cell lines
(Umemura et al., 2003). It has been documented that the same polysaccharide induces
apoptosis in lines of human leukemia (Sogawa et al., 1998). Homopolysaccharide from G.
impudicum in vitro and in vivo, suppresses the development of tumor cells, activating the
immune system.
Proteins, Peptides, and Cancer
As far as proteinic substances are concerned, a large number of microalgae can
produce therapeutic proteins and peptides (Talero et al., 2015). It has been reported
that phycobiliproteins from red-algae Porphyridium sp. demonstrate anti-cancer,
4 Caspase-8 is a cysteine proteases (proteins), which are involving in apoptosis and cytokine processing.
16
antioxidant and anti-inflammatory properties (Romay et al., 2003). Therefore, multiple
microalgae have shown signs of anticancer peptides (Kang and Kim, 2013).
Among them, we can identify a polypeptide from Chlorella pyrenoidosa, Chlorella
vulgaris (Wang and Zhang, 2013). Such compounds have expressed cytotoxic properties
along with antimitotic or proapoptosis function and, in some cases, inhibitory impact
on proteasome5. It can thus be proposed that proteins and peptides produced by
microalgae can aid in preventing and/or treating human cancer. In vivo studies would,
though, be necessary to bring valid conclusions, particularly on humans (Nazih and
Bard, 2018).
3.2. Antiviral activity
Unfortunately, there is no specific vaccine for many viral infections, some
respiratory tract viruses, Herpes Simplex Viruses (HSV-1 and HSV-2), or dengue viruses.
Also, drug resistance by multiple viruses such as HIV (Human Immunodeficiency Virus)
type 1 or HSV-1 to usable antiviral agents has always been a significant barrier to the
treatment of viral infections, prompting the search for new effective molecules
(Ahmadi et al., 2015).
Therefore, methanolic or ethanolic extracts have been used to identify antiviral
agents in microalgae for many years, with success rates in study and implementations
(Lau et al., 1993; Ohta et al., 1998; Fabregas et al., 1999; Bergé et al., 1999; Abdo et al.,
2012; Sanmukh et al., 2014; Ahmadi et al., 2015). These various solvents isolate
antiviral components with environmentally sustainable approaches. For example,
Santoyo et al. (2010) examined the antiherpetic properties of Pressurized Liquid
Extraction (PLE) extracts (hexane, ethanol, and water) from Haematococcus pluvialis
and Dunaliella salina. Pretreatment of Vero cells with 75 μg/mL of H. pluvialis ethanol
extract stopped virus infection by about 85%, whilst the same water and hexane
extract levels diminished the virus infection by 75% and 50%, accordingly. The antiviral
function of PLE water extracts was shown to interact with polysaccharide
concentration; nevertheless, other components, particularly fatty acids, could be
essential for this antiviral activity (Santoyo et al., 2012).
5 Proteasome is an extensive protein complex that causes intracellular protein degradation
17
Purified Molecules
Comparing certain types of molecules, lipids, proteins, or pigments, a broad
spectrum of literature concerns antiviral algal polysaccharides. Ginsberg et al. (1947)
and Gerber et al. (1958) first showed potential antiviral activity for algal
polysaccharides, finding that polysaccharides isolated from macroalgae protected
embryo eggs from influenza B and mump viruses. In general, polysaccharides are
widely cited as having several benefits, such as reduced cost of production, a broad
range of antiviral effects, low cytotoxicity, safety, and strong approval. But such
complex molecules, together with the enzyme's failure to absorb them, aid in the
body's cytotoxic results, which limits their clinical development. Recently, interest in
microorganisms as sources of high molecular weight polysaccharides has grown, as
these biopolymers often have advantages over the commonly produced
polysaccharides (Dewi et al., 2018).
Polysaccharides
As regards red macroalgae, extracellular polysaccharides were the focus of active
research (Geresh et al., 1990, 2002a,b; Huleihel et al., 2001, 2002; Lupescu et al., 1991;
Raposo et al., 2013, 2014a; Shrestha et al., 2004; You and Barnett, 2004). This table
shows various purified polysaccharides of microalgae showing antiviral activities.
18
Table 2: Several purified polysaccharides of microalgae with antiviral activities:
Modified by Dewi et al., 2018.
Compounds Microorganisms Viruses References Rhodophyta Highly sulfated polysaccharide
Porphyridium cruentum
HSV-16, HSV-2, Vaccina
Huang et al., (2005) Raposo et al., 2014a,b
Sulfated exopolysaccharide
P. purpureum Porphyridium sp.
Vaccina HSV-1, HSV-2
Radonic et al., (2010)
Sulfated polysaccharide
Rhodella reticulata
Varicella zoster virus7
Huleihel et al., (2001)
exopolysaccharides Murine sarcoma and leukemia viruses
Radonic et al., (2010) Talyshinsky et al., (2002)
Bacillariophyta Sulfated polysaccharide
Navicula directa HSV-1, HSV-2, Influenza-A; HIV-1
Lee et al., (2006) Ahmadi et al., (2015)
Naviculan Dinoflagellates Extracellular polysaccharide
Gyrodinium impudicum
EMCV 8 , influenza A virus
Yim et al., (2004) Kim et al., (2012)
p-KG03 Extracellular sulfated polysaccharide A1 and A2
Cochlodinium polykrikoides
Influenza A and B viruses, RSV-A9, RSV-B, parainfluenza-2
Hasui et al.,(1995)
Compounds Microorganisms Viruses References Chlorophyta Sulfated polysaccharide
Chlorella vulgaris Dunaliella salina C.autotrophica (chlorella), Ellipsoidon sp. Haematococcus pluvialis
HSV-1 VHSV10, ASFV11 HSV-1
Santoyo et al. (2012) Fabregas et al. (1999) Santoyo et al. (2012)
Sulfated exopolysaccharides from marine microalgae are believed to interact with
the first phase of the development of some enveloped viruses (Batinic and Robey,
1992), therefore blocking the virus from entering the host cells and providing
competitive advantages due to their wide antiviral range, such as against HSV and HIV-
1 (Amaro et al., 2011; Damonte et al., 2004). The sulfated polysaccharide by a cell wall
of the red microalga Porphyridium sp. demonstrated remarkable antiviral capacity
6 Herpes simplex virus 1 and 2 7 is one of eight herpesviruses 8 encephalomyocarditis virus 9 Respiratory Syncytial Virus Subtypes A and B 10 Viral hemorrhagic septicemia 11 African swine fever virus
19
versus HSV type 1 and 2, both in vitro by culturing cells and in vivo by experimenting in
rats and rabbits (Huleihel et al., 2002).
Certain microalgae from different taxonomic categories generate sulfated
polysaccharides with antiviral activity. For example, the diatom Navicula directa creates
an extracellular sulfated polysaccharide, naviculan, consisting of galactose, xylose,
rhamnose, fucose, mannose, and sulfate. Naviculan has a strong antiviral activity
against HSV-1 and HSV-2 and influenza viruses by impeding the early stages of
viral proliferation and may block viral incorporation in host cells (Lee et al., 2006).
The Cochlodinium polykrikoides dinoflagellate provides extracellular sulfated
polysaccharides consisting of glucose, galactose, mannose, uronic acid, and sulfate.
The development of HIV-1, flu A and B viruses, and respiratory syncytial viruses A and
B have been impaired by these polysaccharides (Hasui et al., 1995).
Proteins, Lipids, Pigments
The application of microalgal extracts in antiviral therapy appears to be a
particularly attractive choice due to the large chemical diversity of their bioactive
compounds which are less likely to product resistant mutants than other compounds
during the viral life cycle (Fábregas et al., 1999; Falaise et al., 2016). Firstly, various
microalgae organisms generate antiviral proteins, such as lectins which are
carbohydrate-binding proteins or glycoproteins. During the last decade, the
researchers found that numerous lectins creating anti-HIV activity by attaching directly
and closely to carbohydrate parts at the glycosylated envelope of HIV. Secondly, many
algal lipids have the antiviral activity to a smaller extent relative to polysaccharides and
proteins (Dewi et al., 2018).
The most common are sulfolipids and glycolipids, such as
sulfoquinovosyldiacylglycerides (SQDG), monogalactosyldiacylglycerides (MGDG).
Finally, microalgae formed specific pigments demonstrating similar biological anti-viral
activities. Chlorophyll substances from Dunaliella primolecta have shown anti-HSV
(Herpes Simplex) function (Ohta et al., 1998). Moreover, a water-soluble component
containing marennine, the blue pigment formed by the Haslea ostrearia marine
diatom, was able to block the replication of HSV-1 in vitro (Bergé et al., 1999).
20
3.3. Antibacterial activity
After Pratt et al. pioneering work in the 1940s, which revealed chlorellin's
antibacterial activity, the quest for antibacterial components from microalgae (Falaise
et al., 2016) has created growing interest. This antibiotic, a synthesis of the green fatty
acids Chlorella sp., was demonstrated to be efficient for various Gram positive (G+) and
Gram negative (G−) bacteria (Pratt et al., 1944).
Fatty acids (Desbois et al., 2009; Khoeyi et al., 2012; Sanabria-Ríos et al., 2014),
polyphenols (López et al., 2015), biphenyls (Volk and Furkert, 2006), polysaccharides
(Geresh and Malis, 1991; Raposo et al., 2015), and nanoparticles12 (Garcıa et al., 2014;
Merin et al., 2010; Patel et al., 2015) consist of various antibacterial components from
microalgae. Those substances have different mechanisms to prevent the growth of
bacteria. Fatty acids can affect the permeability of the bacterial cell wall by penetrating
its long carbon chains (Galbraith and Milter, 1973), they can also impede the
development of some bacterial enzymes (Kurihara et al., 1999) and restrict nutrient
uptake from the atmosphere, blocking bacterial growing (Desbois and Smith, 2010).
Polyphenol and biphenyl compounds from microalgae induce bacterial cell lysis by
interfering with membrane permeability and solidity of the phospholipid layer (Daglia,
2012; Jain et al., 2013). Moreover, multiple antibacterial modes of action remain to be
examined, such as nanoparticles limiting bacterial growth (Shankar et al., 2016).
Therefore, screening studies discovered that microalgae are a source of various
antimicrobial agents, due to their species chemodiversity (e.g., Mudimu et al., 2014).
Lastly, a compound's antibacterial efficiency can vary depending on the bacteria's Gram
type. The bacteria (G−) tended to be more tolerant than the bacteria (G+) to several
antibiotic agents. An exception is the appearance of lipopolysaccharides of microalgae
in (G−) bacteria which tends to inhibit the penetration of extracellular compounds into
the bacterial cells (Takeuchi et al., 1999).
Green Microalgae
Recently, microalgae antibacterial compounds have been examined, attesting the
range of compounds being analyzed with biological activities and the abundance of
12 nano-sized materials
21
microalgae organisms (Amaro et al., 2011; Falaise et al., 2016; Pradhan et al., 2014).
Table 3 presents several known compounds with antibacterial efficacy extracted from
microalgae.
Table 3: Antibacterial compound from eukaryotic microalgae: Modified by Dewi et al., 2018
Microalgae Antibacterial Compound Examples of Target Bacteria
References
Green Microalgae Chlorella sp. Mixture of fatty acids Bacillus subtilis,
Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, Pseudomonas aeruginosa
Pratt et al. (1944)
C. vulgaris Phenolic compounds E. coli, Klebsiella sp., Bacillus sp., Pseudomonas sp.
Syed et al. (2015)
C. ellipsoidea Saturated and unsaturated fatty acids
Propionibacterium acnes Sibi (2015)
C. protothecoides C. pyrenoidosa Chlorococcum HS-101
Alpha-linolenic polyunsaturated fatty acid
B. subtilis, B. cereus, S. aureus, MRSA13, Enterobacter aerogenes
Ohta et al. (1995)
C. humicola Pigments (carotenoid, chlorophyll)
B. subtilis, S. aureus, E. coli, P. aeruginosa, Salmonella typhimurium, Klebsiella pneumoniae, Vibrio cholerae
Bhagavathy et al. (2011)
Dunaliella primolecta
Alpha-linolenic polyunsaturated fatty acid
B. cereus, B. subtilis, S. aureus, MRSA, E. aerogenes
Ohta et al. (1995)
D. salina Indolic derivative, polyunsaturated fatty acids, beta-ionone and neophytadiene
S. aureus, E. coli, P. aeruginosa
Herrero et al. (2006)
Mendiola et al. (2008) Pane et al. (2015) Microalgae Antibacterial Compound Examples of
Target Bacteria References
Haematococcus pluvialis
Short-chain fatty acid S. aureus, E. coli Santoyo et al. (2009)
Scenedesmus obliquus
Long-chain fatty acid S. aureus, E. coli, P. aeruginosa, Salmonella sp.
Guedes et al. (2011)
Tetraselmis suecica Fatty acid Proteus sp., S. pyogene Bai and Krishnakumar (2013)
Red microalgae Porphyridium aerugineum, P. cruentum
Phycobiliprotein S. aureus, S. pyogenes Najdenski et al. (2013)
Salmonella typhimurium P. cruentum Extracellular sulfated
polysaccharides S. enteritidis Raposo et al. (2014b)
Rhodella reticulata S. aureus, S. pyogenes, B. cereus, S. typhimurium
Najdenski et al. (2013)
Diatoms Chaetoceros muelleri
Unsaturated fatty acid B. subtilis, S. aureus, E. coli
Mendiola et al. (2008)
Phaeodactylum tricornutum
Fatty acid B. cereus, S. aureus, S. epidermidis, MRSA
Desbois et al. (2009)
Haslea karadagensis
Marennine-like pigment Polaribacter irgensii, Pseudoalteromonas elyakowii, V. aestuarianus
Gastineau et al. (2012b)
Haslea ostrearia Marennine P. irgensii, P. elyakowii, V. coralliilyticus, V. tubiashii, V. aestuarianus
Gastineau et al. (2012a)
Gastineau et al. (2014)
Falaise et al. (2016)
13 Methicillin-resistant Staphylococcus aureus
22
The green microalgae of the Chlorella group contain many antimicrobial compounds,
such as fatty acids, pigments, and phenolic compounds (Jorgensen, 1962). Bacteria like
Escherichia coli, Klebsiella sp., Bacillus sp., and Pseudomonas sp. can be inhibited by
phenolic ingredients such as flavonoids and tannins from methanolic extracts of
Chlorella vulgaris (Syed et al., 2015). Lipid derivatives of Chlorella ellipsoidea, Chlorella
protothecoides, and Chlorella pyrenoidosa show a lipase activity reduction of
Propionibacterium acnes (Sibi, 2015), a (G+) anaerobic bacteria. Furthermore, Ferreira
et al. (2016) analyzed a silver nanoparticle, biosynthesized from C. vulgaris, as an
antibacterial component against Staphylococcus aureus and Klebsiella pneumoniae.
Results indicate that silver nanoparticles blocked both bacteria's activity by 98 percent,
at levels as low as 10 μg /mL. Dunaliella primolecta methanolic samples indicated
significant activity against methicillin-resistant S. aureus (MRSA) (Ohta et al., 1995).
Additionally, methanolic compounds from Dunaliella tertiolecta showed in vitro
antibacterial function towards S. Aureus and P. aeruginosa, bacteria that can create
external otitis (Pane et al., 2015). D. Salina contains various exopolysaccharides, which
are recognized as strong antibacterial agents against E. Coli and S. aureus (Mendiola et
al., 2008). The green microalga Tetraselmis suecica was also confirmed to inhibit the
growth of bacteria. In one study a combination of chloroform and ethanol compounds
is powerful versus Proteus sp. and S. pyogenes bacteria. The fatty acids were identified
as the bioactive compounds in T. suecica (Bai and Krishnakumar, 2013).
Red microalgae
Porphyridium aerugineum phycobiliproteins contain phycocyanin that is
documented to impede the production of the (G+) S. aureus14. In Porphyridium
cruentum, phycoerythrin was described as an antibacterial ingredient against S. aureus
(Najdenski et al., 2013), and 1% of extracellular sulfated polysaccharides (EPS)
demonstrated activity against E. coli and S. aureus (Raposo et al., 2014b). Liberman et
al. (2016) assessed the antibacterial behavior of the Porphyridium sp. polysaccharide
combination with ion Zn2+. In addition to the Porphyridium species, in vitro
experiments with the red microalga Rhodella reticulata using exopolysaccharides
14 Staphylococcus aureus is a Gram-positive, round-shaped bacterium
23
observed antibacterial activity against S. Auroreus, S. Pyogenes, Cereus Bacillus, and
Typhimurium Salmonella (Najdenski et al., 2013).
Diatoms
It is also recognized that several diatom microorganisms have an antibacterial
function. Seraspe et al. (2012) analyzed N-hexane, methanol, dichloromethane, and
ethyl acetate extracts of Chaetoceros calcitrans and this in vitro assessment proved a
growth inhibition of S. aureus, B. subtilis and E. coli. Purified by the diatom
Phaeodactylum tricornutum, the fatty acid eicosapentaenoic acid (EPA) demonstrated
important in vitro activity against S. Aureus (Desbois et al.,2009).
Methanol extracts of Skeletonema costatum showed within vitro assessment
effectiveness against the pathogenic bacteria Proteus mirabilis, Proteus vulgaris,
Proteus aeruginosa, Salmonella paratyphi B, S. aureus, and Vibrio cholerae. (Daniel,
2016). Unpurified compounds of the diatom S. marinoi, under phosphate culture and
nitrogen deprivation, impede S. aureus growth (Lauritano et al., 2016). A concentration
of 100 μg/mL, crude extracts from Amphora cf capitalata, and Nitzschia comunis
stopped S. aureus production by 83% and 100%, respectively (Montalvão et al., 2016).
3.4. Antifungal activity
Many fungal species have reported an invasive infection that can often damage
serious organs such as the skin and the nails, lungs, brain, and all the parts of the oral
and genitals (Husain et al., 2001; Tyagi, 2016). The genera Candida, Cryptococcus,
Aspergillus, and Pneumocystis of fungi are blamed for more than 90 percent of all
fungal-related deaths in persons with reduced immunity (Brown et al., 2012). For
example, on the one hand, dermatophytes are responsible for superficial skin and nails
infections, on the other hand, Candida species causes candidiasis, a very frequent
fungal infection (Tong and Tang, 2017). Candidiasis generally affects the digestive and
respiratory system, bloodstream, and vagina. Cryptococcus neoformans, also causes
another life-threatening infection, cryptococcis. This uncapped yeast can influence the
central nervous system (CNS) and causes brain and meninges inflammation (Chrétien et
al., 2002), but also inflammation of lungs (Fang et al. 2015). Aspergillosis is also a very
24
dangerous fungal infection, mainly due to Aspergillus fumigatus and A. Flavus which
creates pneumonia and weakens the immune system (Latge, 1999). Moreover, these
aggressive fungi, creates nosocomial infections which lead to an increased death rate in
intensive care units (Majumdar and Padiglione, 2012). Pneumocystis infections consist
of another usual respiratory disease, life-threatening when HIV or prolonged
immunosuppressive therapy damages immunity (Brown et al., 2012).
Generally, fungal infection therapy has become increasingly difficult because of
strain resistance (Ghannoum and Rice, 1999). Currently, a preferred approach to deal
with invasive fungal infection is a combination of antifungal medications (Carrillo-
Munoz et al., 2014). Nevertheless, due to the fast and significant spread of resistant
fungi, other therapeutic approaches may need to be developed that require new
antifungal drugs. Specific research on the availability of new sources of antifungal
agents has been performed. Microalgae because of their richness in bioactive
compounds and their versatility, become one of the most valuable candidates of new
antifungal medicines (Skulberg, 2000).
Green and Red Microalgae
Many green microalgae contain organically active compounds, for example, the
Chlorella and Scenedesmus genera, which may be antimicrobial agents. For instance,
the culture liquids from C. vulgaris and C. ellipsoidea had antifungal activity against
Candida kefyr, Aspergillus fumigatus, and Aspergillus niger (Ghasemi et al., 2007).
Often these bioactive substances from microalgae are diffused in organic solvents.
Thus, extracts with various organic solvents (acetone, benzene, chloroform,
diethylether, ethylacetate, ethanol, hexane, and methanol) of the freshwater
Chlorococcum humicola demonstrated antifungal function versus Candida albicans, A.
niger, and A. flavus, and the most powerful from benzene extracts (Bhagavathy et al.,
2011).
Abedin and Taha (2008) also measured the antifungal activity of solvents like
acetone, ethanol, diethylether, and methanol extracts of Chlorella pyrenoidosa and
Scenedesmus quadricauda against A. niger, A. flavus, Penicillium herquei, Fusarium
moniliforme, Alternaria brassicae, Helminthosporium sp., Saccharomyces cerevisiae, C.
25
albicans. Algal extracts showed different inhibitory effects of the fungi tested, with
ethanol extracts to be the most effective.
Because of the low number of available red microalgae, only a few experiments
have taken place, compared to other classes. This explains why Mudimu et al. (2014)
noticed an inhibition activity against C. albicans only in 2 out of 88 microalgal strains,
Heterochlorella luteoviridis and the rhodophyte Porphyridium purpureum.
For example, phycobiliproteins removed from Porphyridium aerugineum and P.
cruentum presented antifungal action against C. albicans, as well as the
exopolysaccharides of Rhodella reticulata (Najdenski et al., 2013).
Diatoms and Dinoflagellates
A large number of diatoms antimicrobials are also a powerful antifungal.
Polysaccharides from Asterionella glaciallis, Chaetoceros lauderi, and Chaetoceros
diadema have strong antifungal function against Candida pseudotropicalis,
Trichophyton rubrum, Fusarium fuhum, Fusarium oxysporum, and Colletotrichum
acutatum (Viso et al., 1987). Besides, since the antimicrobial impact depends on the
emitter as well as on the target organism, Chaetoceros Lauderi show the highest
efficiency towards Fusarium oxysporum.
The efficacy of the antifungal agent also depends on the extraction solvent. Walter
and Mahesh (2000) tested 11 marine diatoms for their antimicrobial function towards 8
pathogenic fungi. Eight of the 11 diatom species examined showed
important antifungal behavior, which differed in intensity accordingly to the solvent
and the target species. The strongest antifungal activity was of Thalassiothrix
frauenfeldii and Navicula sigma, and Aspergillus niger and Cryptococcus neoformans
were the most vulnerable fungi. Acetone extracts seemed to have the lowest antifungal
efficacy, the lowest chloroform-methanol, and methanol-water proportions.
Finally, several dinoflagellates can produce toxins, but some of these toxins are
considered antimicrobial (Camacho et al., 2007; Gallardo-Rodríguez et al., 2012).
Consequently, the dinoflagellate Gambierdiscus toxicus produces polyethers,
gambierdic acids with antifungal effectiveness (Nagai et al., 1993). Gambierdic acid A
and B impeded fungal growth of A. niger and A. fumigatus, as the most sensitive
26
species. Antifungal agents are extracted from Amphidinium sp. dinoflagellates such as
polyol compounds (karatungiols A and B) which block A. niger (Washida et al., 2006).
3.5. Potential of Microalgae in Cardiovascular Disease Prevention
The primary cause of mortality and premature death is cardiovascular disease (CVD).
It covers coronary heart problems, stroke, peripheral artery disease, and heart failure.
Hypertension, hyperlipidemia, and diabetes are the major risk conditions of
atherosclerosis. Different results show that in addition to their specific fatty acid
composition, microalgae may also minimize some of these risk factors and provide a
dietary preventive strategy intrinsically (He et al., 2004). The plasma cholesterol level in
rats has been decreased with the use of red microalga Porphyridium sp. (Dvir et al.,
2000). This effect is mainly due to the microalgae's polysaccharide component, but
other components such as phycocyanin can influence lipid metabolism (Nagaoka et al.,
2005). In addition to these animal studies, microalgae's hypolipidemic activity was used
in human clinical studies (Nazih and Bard, 2018).
The Omega-3 Index was introduced in 2004 as a modern measure of risk concerning
cardiovascular mortality. Though initially synthesized by microorganisms in the seas,
the long-chain n–3 (omega-3) fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) are mainly produced from fish consumption (Harris, 2014).
Fish and fish oil are indeed the main sources of polyunsaturated fatty acids (LC-PUFA)
in the omega-3 long-chain, however, contaminants or toxins have been increased in
fish. Also, using fish oil is relatively poor in part owing to odor, taste, and oxidation
issues (Mimouni et al, 2015). Because of these drawbacks, studies have been published
for an application of microalgae (marine or freshwater) in human aliment, as a new
source of fatty acids, according to their versatility of lipids and fatty acids. Even if still in
its development, a near-infinite supply of these essential nutrients will be generated by
commercial production of EPA and DHA from nonfish origins (Adarm-Vega et al, 2012).
Freshwater microalga Chlorella vulgaris produces oleic, palmitic, and linolenic acids
(Mendes et al., 1995). Dunaliella salina generates fatty acids in a percentage of about
80% of the overall fatty acids (Herrero et al., 2006). Porphyridium species can also
extract gamma-linolenic and arachidonic acids. Other species of microalgae synthesized
27
omega-3 fatty acids, such as EPA in genus Nannochloropsis, Phaeodactylum, Nitzschia,
Odontella, Isochrysis, and Pavlova species, although DHA can be found in the
Crypthecodinium, Pavlova and Schizochytrium ones. Additionally, few species of these
microalgae are approved for commercial use as nutritional supplements, Chlorella,
Crypthecodinium, Dunaliella, and Odontella (Rodriguez-Meizoso et al., 2010).
In the latest decades from the advent of healthy supplements with probiotics, the
health benefits of microalgae have been gradually recognized and accepted, especially
in cardiovascular diseases. Another freshwater microalga, Chlorella sp., has had many
health benefits, such as a reduction of glycemia and cholesterolemia. Such organisms
could also be used to improve the development of cytokines to enhance the response
of the immune system (Barrow and Shahidi, 2008).
Although few strains of microalgae have been approved for human consumption,
animal models have performed several trials with several microalgae. Also,
Porphyridium cruentum lyophylisate was utilized for the Syrian golden hamster as a
food additive. This test showed the reduction in cholestine distribution (dose-
dependent) and body fat (percentage-expressed) in hypercholesterolaemic animals
with the use of this microalgae biomass (Harding et al., 2009).
Retinoids, the metabolic components of carotenoids, are significant in the growth of
the cardiovascular system during embryogenesis. This function is regulated by
triggering the RAR (retinoic acid receptor) in the signal transduction pathways
controlling the growth of embryos, tissue homeostasis, and cell division and
multiplication. Nonetheless, earlier studies have shown that retinoids play a significant
role in cardiac repair after myocardial infarction in hypertensive rats (Paiva et al, 2005).
Carotenoids, these plant pigments synthesized first retinol then retinoic acid (RA) in the
intestine, the liver, and eventually in target cells. RA is important to modify several
biological processes such as cell replication and growth, vision, bone formation,
metabolism, and immunology. The medical research of retinoid derivatives as
medicines for the treatment of many diseases is, therefore, very promising (Das et al,
2014).
Dunaliella Salina which is unicellular and part of the phylum chlorophylta, is known to
be the largest natural source of large carotenoids (Phadwal et al, 2003). Zeaxanthin,
one of nature's most abundant carotenoids, is an antioxidant. Consequently,
28
Zeaxanthin isolated from D.salina can be used as a natural medicinal agent by
activating retinoid receptors in cardiac tissue to improve heart damage (El-Baz et
al,2019), while it is proven a promising curative and prophylactic activity of D. salina
against cardiac dysfunction in aging rats (El-Baz et al, 2018).
Astaxanthin is a carotenoid of xanthophyll contained in microalgae. It is an
antioxidant with anti-inflammatory effects and therefore has potential as a therapeutic
drug in coronary atherosclerotic diseases. A small number of clinical trials have
examined the efficacy of astaxanthin on oxidative stress and inflammation that are
important to the pathophysiology of cardiovascular diseases. Laboratory research of
multiple species using a myocardial ischaemia-reperfusion model has shown that
astaxanthin supports myocardium both orally and intravenously before the ischaemic
event is inducted (Fassett and Coombes, 2011).
Astaxanthin has a special molecular structure, which controls its intense antioxidant
activities by purifying singlet oxygen15 and free radicals. Astaxanthin was indicated to
reduce oxidation of low-density lipoprotein (LDL) (bad cholesterol) and to improve
clinical trial levels of high-density lipoprotein (HDL)-cholesterol and
adiponectin (peptide) (good cholesterol particle). Current evidence indicates that the
potential of astaxanthin for improving oxidative stress, inflammation, lipid metabolism,
and glycosemia may contribute to preventative measures against atherosclerotic
cardiovascular disease (Kishimoto et al, 2016).
The largest amount identified of astaxanthin in nature is Haematocaccus pluvialis, a
chlorophyte alga that has to turn into a major source of astaxanthin in the food field
(Lorenz and Cysewski, 2000; Yuan et al, 2011). In 1987, the United States FDA
permitted astaxanthin as a food supplement for the aquaculture sector and in 1999
authorized astaxanthin as a nutritional supplement (Guerin et al, 2003).
15 gaseous inorganic chemical
29
Table 4. Summary of the anti-atherosclerotic activity of astaxanthin:
Modified by Kishimoto et al, 2016.
Anti-Oxidation
Iwamoto et al. (2000)
Healthy volunteers (n = 24)
Open labeled; 2 weeks; 1.8, 3.6, 14.4 or 21.6 mg/day
(decrease)LDL oxidation
Nakagawa et al. (2011)
Middle-aged subjects (n = 30)
Randomized, double-blind, placebo controlled; 12 weeks; 6 or 12 mg/day
(decrease) phospholipid peroxidation 16 in erythrocytes
Karppi et al. (2007)
Healthy non-smoking males (n = 40)
Randomized, double-blind, placebo controlled; 12 weeks; 8 mg/day
(decrease) plasma 12- and 15-hydroxy fatty acids
Choi et al. (2011)
Overweight adults (n = 23)
Randomized, double-blind; 3 weeks; 5 or 20 mg/day
(decrease) plasma MDA17(marker of oxidative stress), isoprastane 18 �(increase) SOD19, TAC 20
Anti-Inflammation
Park et al. (2010)
Healthy female students (n = 42)
Randomized, double-blind, placebo controlled; 8 weeks; 0, 2 or 8 mg/day
(decrease)plasma 8-hydroxy-2- deoxyguanosine21 , CRP22
Lipid Metabolism-Modulating
Yoshida et al. (2010)
Non-obese subjects with mild hypertriglycemia (n = 61)
Randomized, placebo-controlled study; 12 weeks; 0, 6, 12 or18 mg/day
(decrease) serum TG, �(increase) HDL-C, adiponectin23
Ursoniu et al. (2015)
Meta-analysis of seven randomized controlled studies
No important effect on plasma lipid profile (LDL-C, HDL-C, TG24)
Glucose Lowering
Ursoniu et al. (2015)
Meta-analysis of seven randomized controlled studies
Slight reducing reaction to plasma glucose
For clinical settings, the current data may be positive, but the medicinal efficacy of
this natural compound needs to be identified for human beings.
16 Oxidative degradation of lipids 17 Malondialdehyde (MDA) is one of the final products of polyunsaturated fatty acids peroxidation in the cells. 18 Biomarkers serve as indicators of oxidative stress in cardiovascular diseases. 19 Antioxidant enzyme that reduces harmful free radicals 20 total antioxidant capacity 21 products of DNA oxidation 22 protein, marker of inflammation 23 a protein hormone that is produced by fat cells. 24 Thyroglobulin, glycoprotein produced by the follicular cells of the thyroid
30
3.6. Metabolism
Metabolism defines all chemical reactions involved in the preservation of the cell
and the organism's living state. The major public health concern is metabolic syndrome
causing dyslipidemia, obesity, and insulin resistance which leads to cardiovascular
disease and death. Omega-3 PUFA in fish oil is well proven to lower the frequency of
metabolic syndrome risk elements (Poudyal et al., 2011). An additional source of
Omega-3 is from Odontellla aurita marine diatom which synthesizes high levels of
eicosapentaenoic acid (EPA, 25 to 26% of total fatty acids) which is known to obstruct
cardiovascular risks. O. aurita's efficiency as a food supplement is proved by Mimouni
et al (2015), in controlling physiological and biochemical parameters involved in
metabolic syndrome deployment, platelet aggregation,25 oxidative stress which leads
to cardiovascular health problems.
Another serious health problem due to the modern lifestyle is obesity. The anti-
obesity activity of refined FX powder (Phaeodactylum extract (PE)) from microalgae
Phaeodactylum tricornutum as a functional food has been explored in the other
research (Koo et al, 2019). PE containing FX exercises anti-obesity functions and
facilitates lipolysis via lipogenesis inhibition. It is, therefore, a good candidate in the
production of antiobesity foods and integrated health foods produced by modern
marine microalgae.
Diabetes mellitus (DM) is a category of metabolic disorders with a high level of blood
sugar for a long time. Serious long-term problems from diabetes include heart attack,
stroke, chronic kidney disease, foot ulcer, and eye injury (www.wikipedia).
An assessment of antihyperglycemic and antihyperlipidemic behaviors and weight
monitoring of Nannochloropsis oculata microalgae (NOM) in Streptozotocin26-induced
diabetic male rats were performed by Nasirian et al., in 2019. Other studies have
shown that the treatment of chlorella microalgae in diabetic rats has lowered glucose
levels and increased insulin levels (Mokady and Sukenik, 1995). In this test, NOM
therapy significantly decreased plasma TG27, total cholesterol and LDL-C associated
25 Aggregation of platelets is part of the sequence of events that contribute to thrombal formation (clot). 26 is consisting an alkylating antineoplastic agent founded in the nature which is very toxic to the insulin-producing beta cells of the pancreas in mammals. 27 triglyceride levels
31
with a significant increase in HDL-C rates in diabetic rats in three weeks, showing its
strong antihyperlipidemic and anti-atherogenic action.
Markovits et al. (1992) also stated that dietary fibers existing in Nannochloropsis, in
particular, insoluble fibers, inhibit intestinal absorption of cholesterol (Kagan et al,
2014) and have an anti-hypercholestromic effect. Diabetic rats (control group) display
less body weight than healthy rats. NOM can retain weight in diabetic rats and improve
metabolic disorders by increasing insulin and reducing the level of glucose. However,
the antioxidant pigments and EPA28 present in the NOM will retain glucose, insulin, and
lipid profile values, and can boost body metabolism and therefore maintain weight.
These findings suggest that NOM can be beneficial for diabetes mellitus care. Further
research will be needed in the relationship between NOM and diabetes.
Moreover, diabetic rats have seen decreased values of glucose and lipid
(triacylglycerol and cholesterol) and it is a proven loss of weight in groups fed with
microalgae Isochrisis Galbana. About the synthesis of lipoproteins, this microalga raises
law lipoprotein content and reduces the concentrations of large lipoproteins (Nuno et
al. 2013).
3.7. Respiratory
Acute respiratory distress syndrome (ARCS) is considered an immediate start of
noncardiogenic edema and as a result of severe inflammatory processes, an obstacle of
gaz-exchange. Ω-3 fatty acids have been suggested to modulate the inflammatory
response in ARDS, even though the data so far collected is limited (García de Acilu et al,
2015).
3.8. Inflammation-Oxidative Stress-Allergies
The incidence of oxidative stress and inflammatory disorders in developed countries
is steadily growing (Bonomini et al, 2008; Molodecky et al, 2012). The development of
these conditions may also be correlated with cancer (Reuter et al, 2010; Siegel et al,
2016). Studies are, therefore, trying to trace new compounds that can be applied to
decrease inflammation, oxidative stress and cancer cell activity. A lot of proves are
32
available in the literature, indicating that certain microalgae extracts have an anti-
inflammatory effect. Nevertheless, aqueous extracts of both microalgae decreased paw
edema in rats caused by carrageenan (Guzman et al., 2001).29 The inflammation was
decreased by 90 percent with Chlorella stigmatophora at a dosage of 250 mg/kg and
with Phaeodactylum tricornutum by 87%. The anti-inflammatory activity of coarse
extracts was 25%-30% higher than indomethacin30, the pharmacological equivalent
(Nazih and Bard, 2018).
The researchers proposed that these results could be due to phycocyanin because
both oxidative stress and edema were prevented by this molecule; this anti-
inflammatory activity may also be due to the presence in microalgae of sulfated
polysaccharides.
In a test utilizing polysaccharides obtained from Porphyridium microalgae, it was
shown in vitro that these polysaccharides prevented leucocyte chemotaxis and
endothelial cell adherence. Such compounds have also been evaluated in human
volunteers with a background of skin allergy to balsam of Peru (Matsui et al., 2003).
Microalgae-based polysaccharide fractions reduced skin redness even more than an
active anti-inflammatory compound derived from a cola extract. Such results indicate
that these extracts might be utilized for external use as effective anti-inflammatory
drugs.
Moreover, Fucoxanthin, this oxygenated carotenoid from diatom Phaeodactylum
tricornutum, may be used as a new nutraceutical if it also has the positive health
effects that have already been shown for microalgae carotenoids. In cell-free and cell-
based assays, Fucoxanthin had powerful antioxidant effects. Fucoxanthin's antioxidants
extracts from P. tricornutum do not vary greatly from astaxanthin, a carotenoid that
has powerful antioxidant effects produced from the already commercially marketed
red algae Haematococcus pluvialis. High amounts of fucoxanthin could be found in the
diet to mitigate the effects of oxidative stress-related diseases. However, because of its
protective health effect, fucoxanthin may assist in conventional cancer treatment. To
28 eicosapentaenoic acid, fatty acid 29 Carrageenans or carrageenins are sulfated polysaccharides derived from red edible seaweeds. 30 An anti-inflammatory medicine
33
further endorse these observations, human trials are needed in the future (Newman et
al, 2019).
Finally, several microalgae species have been identified as anti-allergic. The
existence of an antiallergic substance in the ethanol-insoluble fraction of Dunaliella
salina is strongly suggested (Fujitani et al., 2001). For their anti-allergy characteristics,
other species such as Chlorella vulgaris or Chlorella pyrenoidosa (Chlorophyta) have
also been presented (Vo et al., 2012).
3.9. Immunology (various & infectious diseases)
It is difficult to differentiate the immunomodulative effect of microalgae from the
anti-inflammatory effect. The reported capacity of microalgae polysaccharides to
suppress leucocyte migration may be correlated with their anti-inflammatory function
(Matsui et al., 2003). Nevertheless, certain microalgae have been shown to have a
strong stimulating influence on immune cells.
This was the example of Phaeodactylum tricornutum, which was demonstrated to
trigger phagocytosis and the sulfated polysaccharide from Chlorella stigmatophora,
which indicated immunosuppressant functions (Guzman et al., 2003). Gymnodinium
impudicum sulfated polysaccharides also enable nitric oxide synthesis and induce
cytokine development in macrophages (Bae et al., 2006). However, in contrast to these
promising in vitro and animal findings, there is a distinct deficiency of clinical studies to
suggest that microalgae are of significant interest as a source of compounds for the
treatment of human inflammation or immunomodulation (Nazih and Bard, 2018).
34
Table 5. Marine microalgae producing immunomodulatory compounds or displaying
immunomodulatory properties. IL is for interleukin, PBMC is for human peripheral
blood mononuclear cells. Modified by Riccio and Lauritano, 2019.
Microalgae Extract/Fraction/ Compound
Mechanism/ Organism and Target Cells (or Model)
Reference
Alexandrium tamarense
Total Extract/Fractions
Activation of IL-6/Human PBMC
Cutignano et al, 2015
Chaetoceros calcitrans
Fractions
Activation of IL-6/Human PBMC
Cutignano et al, 2015
Chaetoceros socialis
Total extract
Activation of IL-6/Human PBMC
Cutignano et al, 2015
Chlorella stigmatophora
Crude polysaccharide extracts
Activation of phagocytic activity - SRBC/Mouse
Guzmán et al, 2003
Chlorella vulgaris
Diet supplementation/ commercially available pills
Improve of NK activity and serum level of INF- , IL-1 and IL-12/Human trials
Kwak et al, 2012
Dunaliella salina
Diet supplementation of commercially available spray-dried preparations
MiceNK and Macrophage activation/In vivo mice model
Chuang et al, 2014 Cutignano et al, 2015
Dunaliella salina
Fractions
Activation of IL-6/Human PBMC
Cutignano et al, 2015
Euglena gracilis
β-Glucans
Activation of NK cells and improve in inflammatory mediator/Human PBMC
Barsanti and Gualtieri, 2019 Russo et al., 2017
Gyrodinium impudicum
Sulfated exopolysaccharides
Macrophage activation/Murine
Bae et al, 2006 Yim et al, 2004
Skeletonema costatum
Total Extract/Fractions
Activation of IL-6/Human PBMC
Cutignano et al, 2015
Skeletonema dohrnii
Total Extract/Fractions
Activation of IL-6/Human PBMC
Cutignano et al, 2015
Skeletonema marinoi
Total Extract
Activation of IL-6/Human PBMC
Cutignano et al, 2015
Tetraselmis chuii
Orally administration of lyophilized microalgae
Increase in hemolytic complement activity, phagocytic capacity and expression levels of β-defensin, major histocompatibility complex II a and colony-stimulating factor receptor-1/ Gilthead sea bream
Cerezuela et al, 2012
Thalassiosira weissflogii
Fractions
Activation of IL-6/Human PBMC
Cutignano et al, 2015
Tribonema sp.
Sulfated polysaccharides
Macrophage proliferation and improved expression of cytokines/Mouse
Chen et al, 2019
35
As stated in Table 5, dried algae and crude extracts have been effective versus many
cells of the immune system. Cutignano et al., (2015) examined unrefined methanol
fragments and amounts of different species of microalgae. Fractionation also managed
to distinguish active fractions for other organisms whose raw methanol extracts were
not effective (Riccio and Lauritano, 2019). To determine their immunostimulatory
function, other compounds extracted from microalgae have been studied. Chlorella
stigmatophora polysaccharide aqueous compounds have been analyzed in vitro and in
vivo mouse models (Guzmán et al, 2003). Supplementation of microalgae food was also
correlated with immunostimulatory function. In fact, diet supplements of commercially
accessible spray-dried products of Dunaliela salina in mice boosted NK (natural killers)
and macrophage activation, leading to the survival of leukemic mice (Chuang et al,
2014).
Table 5 lists the algae with immunostimulatory function.
3.10 Hepatology
Chlorella vulgaris has been recorded for reducing dyslipidemia and high blood
pressure; Its impact on inflammatory and insulin-resistant biomarkers, however, has so
far not been discovered. Non-alcoholic fatty liver disease (NAFLD) is strongly associated
with insulin-resistance and inflammation as a hepatic complication of metabolic
syndrome. C. vulgaris supplementation may have beneficial effects as far as glucose
homeostasis, insulin condition, and biomarkers related to inflammation in patients with
NAFLD. C. vulgaris supplementation could be considered as a part of treatment for
weight loss and improvement of glycemic situation and reduction of hs-CRP31 together
with the improvement of the liver condition in NAFLD as stated Ebrahimi- Memeghani
et al. (2017).
31 The increased risk of heart attack is associated with high levels of hs-CRP (high sensitivity C-reactive protein in our blood)
36
3.11 Dermatology
Astaxanthin, a secondary metabolite produced in nature by a series of bacteria,
microalgae, and yeasts, is xanthophyll carotenoid. Traditionally, chemical synthesis has
been used for commercial production, but the Haematococcus pluvialis microalgae
seem to be the most important path for its commercial biological supply. Because of its
common and complex function in skin biology, astaxanthin has various health benefits
and significant nutraceutical uses in dermatology (Davinelli et al, 2018). The
Haematococcus pluvialis chlorophyte algae have the largest potential for the
concentration of ASX (Boussiba, 2000). The strong antioxidant function and special
molecular and biochemical properties of ASX have recently drawn researchers' interest,
for the treatment and prevention of skin disease. Comparative studies studying
carotenoid photoprotective activity have found ASX to be a supreme antioxidant and
more antioxidant compared to canthaxanthin and carotene in human epidermic
fibroblasting (Camera et al, 2009).
Therapy also, with ASX prevents deleterious effects of UV by reducing the
production of UV-induced reactive nitrogen, inflammatory cytokine, and keratinocyte
apoptosis. Inhibitory properties of ASX on iNOS32 are important in developing anti-
inflammatory medicines for skin inflammatory conditions like psoriasis and atopic
dermatitis (AD) (Park et al, 2017). As far as immune effects are concerned, ASX greatly
affects immune function across in vitro and in vivo assays (Lin et al, 2015). In several
studies, ASX increased its natural killer activity (NK) and indicated that ASX may control
NK cells, which serve as a tumor and virus-cell immunosurveillance system (Chew et al,
2011). Moreover, ASX effectively eliminates in vitro cell damage from free radicals and
MMP-133 entry into the skin after UV radiation (Suganuma et al, 2010). In specific, ASX
was able to minimize the damage of DNA and influence DNA repair kinetics (Santocono
et al, 2006). To fully understand ASX skin activities, further, systematic research will be
required.
32 Nitric oxide synthases (NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) from L-arginine. 33 Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation,
37
38
Table 6: Studies on skin and astaxanthin. Modified by: Davinelli et al, 2018.
Intervention
Study Design
Outcomes
Author, Year
Administration of ASX capsules
Randomized double-blind, controlled study
p DNA damage biomarkers; n of NK cells, T cells, B cells, and IL-6
Park, 2010
Administration of ASX capsules
Monitoring of oxidative stress and skin aging
p MDA; pRSSC
Chalyk, 2017
Administration of ASX capsules
Randomized, double-blind, parallel-group, placebo-controlled
pWrinkle parameters; p IL-↵
Tominaga, 2017
Administration of ASX cream
Pilot study 34
pWrinkle parameters
Seki, 2001
Topical application of ASX
Pilot study perythema Yamashita, 1995
Administration of ASX capsules
Randomized, single-blind, placebo-controlled
pWrinkle parameters
Yamashita, 2006
Oral and topical treatment with ASX
N/S
pWrinkle parameters
Tominaga, 2009
Two oral forms (ASX capsules; tablets collagen)
Randomized, double-blind placebo-controlled
nviscoelastic parameters; pTEWL;" procollagen type I; nMMP-1 and pMMP-12
Yoon, 2014
Capsules of ASX combined with topical application of ASX
Open-label noncontrolled
pwrinkles; page spot size; n"elasticity; n"skin texture
Tominaga, 2012
Administration of ASX capsules
Randomized double-blind controlled
pwrinkles; n"elasticity; pTEWL; n"moisture content; psebum oil
Tominaga, 2012
Abbreviations: "nincrease;pdecrease; ASX, astaxanthin; NK, natural killer; IL-6, interleukin-6; MDA, malondialdehyde;
RSSC, residual skin surface components; N/S, not specified; TEWL, transepidermal water loss; MMP, matrix
metalloproteinase.
34 A pilot study is a small scale preliminary study
39
3.12 Neuroscience
The disorder of Parkinson is mainly characterized by dopaminergic 35 neuron
degradation. Neuroinflammation is an important element that damages cells during
disease progression, and experimental settings have been effective in reducing the
inflammatory process. Fractalkine36 signals have proved to be a crucial path in
inflammatory cell death in animal PD models. Astaxanthin has several biological
functions, many of which seem to be specifically contrasting with the pathological
mechanisms involved in SN37 neurodegeneration. The two promising new therapeutic
agents for PD diagnosis and management include both fractalkine and astaxanthin
(Grimming et al., 2016).
Alzheimer’s Disease (AD) is a neurological dysfunction occurring through complex
mechanisms of pathology and physiology. AD leads to dementia, cognitive decline, loss
of synapses and cholinergic neurons, and death. Increasing numbers of AD patients
have centered research into new drugs with minimal or no side effects relative to
conventional pharmaceutical goods (Rajakumar, 2018). With the expectation that
experts will soon be able to reverse AD, prevention measures such as lifestyle changes,
exercise and the use of antioxidants can be taken to delay the progression of AD or to
mitigate it.
So how can microalgae lead to AD treatment? Microalgae are important sources of
many bioactive materials such as carotenoids, polysaccharides, PUFA's, amino acids
and proteins, sterols and polyphenols (Olasehinde et al., 2017). A major cause of a
cognitive decline in patients with AD is accelerated deterioration of the function of
acetylcholinestrase (AChE).38 ACh, which eventually causes cholineergic damage and
memory loss, is impaired due to high cholinesterase concentrations (ChE). The AChE
inhibitory behaviors were contained in extracts from Nannochloropsis oculata,
Chlorella minutissima, Tetraselmis chuii and Rhodomonas salina (Custódio et al., 2012).
35 Dopamine is one of the chemicals that is responsible for signal processing between the neurons of the brain and between nerve cells. 36 anti-inflammatory cytokine (protein) 37 The substantia nigra (SN) is a midbrain-located basal ganglia system that plays a significant role in reward and mobility. 38 The major enzyme of neurotransmitter acetylcholine (ACh) is responsible for its hydrolytic synthesis.
40
Extracts from Nannochloropsis sp., Picochlorum sp., and Desmochloris sp. have been
reported to exhibit BChE39 inhibitory activities (Pereira et al., 2015).
3.13 Ophthalmology
Zeaxanthin, one of nature's most abundant carotenoids, is an antioxidant that
accumulates in the human eye's retina and protects the retinal system against light-
induced harm. Eating diets containing higher levels of zeaxanthin were found to be
followed by a low incidence of eye disorders such as age-related macular diseases, and
cataracts (Madhavan et al, 2018).
39 is a nonspecific cholinesterase enzyme
41
4. European Regulations concerning Microalgae
First and foremost, the EU legal framework for microalgae-based medicinal products
provides certain requirements to secure a high level of public health safety and the
quality, consistency, and effectiveness of licensed medicinal products. Also, not only
can it promote the pure functioning of the internal market but also encourage
innovation progress (Europa, 2019). In Europe, the EFSA (European Food Safety
Authority) is the competent authority ordered to evaluate the safety of any new
functional food and supplement ingredient before they are licensed for production and
market introduction (EFSA, 2019).
Three-pillar European legislation applies to the regulation of microalgae or its
components. The first pillar focuses on general supplement safety, the second one on
novel ingredients, and the last one on functional nutrition and health claims
(Novoveská et al, 2019).
The safety pillar for microalgae nutraceutical products is mainly combined by the
European Commission (EC) No 178/200240 and 852/200441 regulations. The EC No
178/2002 regulation provides a general framework in the development of any
supplement legislation and determines the general definitions, regulations, and
responsibilities during the process of production, distribution, and safety at the
Community level. It also establishes the European Food Safety Authority (EFSA) and
refers to the commercialization of supplement products using either whole microalgae
organisms or cells, such as Spirulina and Chlorella, or products that incorporate the
micro-algae such as the green algae color pasta. Both EC No 178/2002 and 852/2004
state that all these products based on microalgae are subject to regulations on food
safety which apply to all supplementary products. Experts issue that safety is an
important factor in algae-technology especially when algae are generated in open-air
systems because they have proved to be easily contaminated by other microorganisms
(Enzing et al, 2014). The safety of the supplement must be checked in extended use
40 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32002R0178&from=EL
42
because products containing microalgae can not be approved in the European market
without health evaluation being carried out first (Serafini et al, 2010).
As far as pharmaceuticals are concerned the European Medicines Agency (EMEA) is
responsible for securing a commercial authorization application for the EU under the
“centralized” process. Authorization for use is generally required for 1) all prescription
biotech products, 2) pharmaceuticals with a newly formed active ingredient used for
the treatment of HIV, cancer, neurodegenerative disorders, and diabetes, and 3)
medicinal drugs known as "orphans42". In the sense of "decentralized practice," the
“mutual recognition” concept extends to the Member States at a national level.
According to Article 8 of Directive 2001/83/EC43, an authorization may only extend to
organizations set up in an EU country. Whether the trials are carried out or not within
the EU, the clinical studies have been morally implemented and protected the privacy
of individuals. In the appendix of directive 2003/63/EC44, the specific guidelines for
clinical studies are imposed. The Commission regulations set strict deadlines to
approve or deny a request for marketing authorization. The EMEA or the Member State
authorities shall decide in 210 days, in compliance with both decentralized and
centralized policies.
The present European policy on data protection offers a period of “8+2+1” years:
Generic manufacturers may apply for a marketing license of the provided medicine
eight years after a marketing authorization of the original product, but only two years
later could the genetic product in question become available on the market. In case of
the discovery of new therapeutic benefits in the first 8 years data security can be
extended by one year. Data and ads on prescription drugs are severely restricted (EU,
Pharma, legislation, 2019).
41 https://eur-lex.europa.eu/legal-content/EL/TXT/?uri=CELEX%3A02004R0852-20090420 42 The aim of ' orphan drugs ' is to treat diseases that are so rare. 43 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02001L0083-20121116&qid=1472567249742&from=EN 44 https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32003L0063
43
5. Swot analysis – A case study of a fictional microalgae-based carotenoid production company
In this section, the strengths, weaknesses, opportunities, and threats (SWOT
analysis) of a fictional microalgae-based carotenoid production company are
presented.
Strengths
x One of the major strengths of the industry is that there is a rich diversity in terms of
microalgae and carotenoids. As such, carotenoids based on their antioxidant
properties continue to increase interest in multiple markets, including food and feed
products, nutritional products, and cosmetics.
x Furthermore, the fact that carotenoid’s source is natural, adds an advantage for use
of the specific products.
x The further benefits ensuing from other compounds existent in microalgae are
adding forces to the industry.
x The ongoing increasing awareness and enthusiasm of consumers for green chemistry
is another advantage towards future expansion of the specific markets.
Weaknesses
x One of the major weaknesses of microalgal carotenoids is undoubtedly their
currently increased costs of production as it can be exhaustive labor and costly
operation. It is imperative that new methods need to be developed in order to drive
costs further down. Microalgae are cultivated in open ponds or closed systems
requiring procedures of mixture and concentration (Chew et al., 2017). These
procedures are energy consuming and the major concern is minimum energy in
combination with maximum exploitation of microalgae biomass (Vanthoor-Koopmans
et al., 2013). Although open structures for cultivation, like open ponds or raceway
ponds, are more commercially viable for large-scale production, they may not be
appropriate for cultivating microalgae which would be employed on medicinal or
pharmaceutical purposes (Chisti, 2007; Milano et al., 2016). On the contrary, closed
culture systems (e.g. photobioreactors) (Costa and De Morais, 2011; Khoo et al.,
44
2011) are more practicable by monitoring the cultivation conditions (e.g.,
temperature, pH and CO2 concentration, and so on), even if capital and operating
costs rise.
x The biological systems entail some inherent challenges that constitute another
weakness of the industry. The microorganisms that manufacture carotenoids typically
have a low rate and target productivity of carotenoids in accordance with
recalcitration, resulting in inefficiencies in the extraction of the carotenoid. The
biomass must be collected after harvesting in a system separating the solid material
(biomass) from the liquid (cultural medium). The biorefinery process uses microalgae
biomass to create renewable carotenoid products with many advantages like quick
maturation, increased demand on the food industry, and selective composition
(González-Delgado and Kafarov, 2011).
x Downstream processing and the associated weaknesses of the specific methods
constitute further disadvantages.
x Climate limitations for open systems pose further barriers to the industry.
Opportunities
x There is an increase in end-user applications for carotenoid products formulating
niche markets. Consequently, the advance of the aquaculture industry, the medicinal
applications spread, and the increasing preference of consumers for natural
products, support carotenoids from microalgae potential for future revenue growth
(Ambati et al, 2019)
x Improvements in cultivation and downstream processing. The microalgal cultivation
systems (smart microalgae screening and strain enhancement included) are steadily
being developed, while carotenoid extraction methods become more efficient and
environmentally friendly.
x Increasing end-user awareness is apparent. The end-user numbers are constantly
increasing with evident interest in health and sustainability-oriented lifestyles that
encourage the development of sustainable natural carotenoids.
x Future research (a combination of natural and synthetic production). In future
research, there are numerous opportunities, including evolving carotenoids, new
45
applications, and innovations. The development of markets (both niche and
commodity) will expedite the research as well.
Threats
x Stringent regulations are one of the main concerns of the industry and adaptation to
the strict requirements undermines the rapid development of the industry.
x Low-cost competition from Asian countries (due to lower labor and production costs
in such labor-intensive industry) creates concerns for the western carotenoid
markets. On the other hand, such Asian markets provide a huge number of
consumers with inexpensive carotenoids increasing in such a way the total market.
x Very low cost of synthetic production consists of a threat as in the laboratory it is
hard to differentiate natural and synthetic carotenoids unless specialized techniques
such as isotope ratio mass spectroscopy are applied (Kroll et al, 2008). Therefore,
manufactured pigments will quickly enter the market, pretending to be falsely
natural products.
x The potential of contamination of biomass in an open system renders a necessity to
manage the process with extravagant care.
x Impact on Algae Production Due to Climatic Conditions (HTF, 2019)
x As the process is not well-established yet it is a possible threat for any company
entering the specific industry.
46
Table 7: A Swot analysis for microalgae-based carotenoid production companies
Strengths Weaknesses x Rich diversity in terms of microalgae and
carotenoids applicable in multiple markets.
x Natural source of carotenoids. x Benefits from other compounds existent
in microalgae. x Consumer’s awareness and enthusiasm
for green chemistry.
x Increased costs of production. x Inherent challenges of biological
systems. x Downstream processing weaknesses. x Climate limitations for open systems.
Opportunities Threats x Increase in end-user applications for
carotenoid products and for natural products.
x Improvements in cultivation and downstream processing.
x Increasing end-user awareness. x Future research (combination of natural
and synthetic production).
x Stringent regulations. x Low-cost competition from Asian
countries creates concerns to the western markets.
x Very low cost of synthetic production. x Potential of contamination of biomass
in open system. x Impact on Algae Production Due to
Climatic Conditions. x Not yet well-estabished process poses
threats to any incoming company.
47
6. Conclusions
The analysis of scientific data reveals that microalgae were commonly used for the
development of different bioactive compounds as a renewable resource.
The following development limitations could be regarded to optimize possible future
success and restricting the limitations of microalgae biotechnology applications:
x Therefore, it is critical to assure the quality and safety of the microalgal biomass
and its ingredients for the consumption of human beings (as per the FDA and
other regulatory agencies, EFSA, EMEA). On the other hand, the strict public
European regulations for pharmaceutical and nutraceutical products delay the
emergence of new drugs with potential health benefits. A middle way must be
found so that regulations could be respected protecting humans without impeding
the production of new promising medicines.
x Research on the clinical validity of the nutraceutical and medicinal benefits of the
bioactive products extracted from microalgae shall further enhance their
acceptance.
x The lack of clinical studies with humans is the main obstacle that postpones the
significant research to proceed. In a lot of studies, the conclusion was that human
clinical researches must be conducted in order to evaluate the scientific
conclusions or tests on animals.
x Many positive health effects will likely be found with increasing microalgae
consumption as food supplements, nutraceutical, pharma, and cosmetic products.
x Intensive bioprospecting should be pursued by the newer bioactive microalgal
species (Nethravathy et al, 2019).
x A comprehensive attempt should be made to evaluate the sustainability process
through the techno-economic study, environmental efficiency, and life cycle
assessment for the production of high-value microalgae metabolites.
x To improve the process chain and business portfolio, the identification of the
important factors in the manufacture, refining, storage, marketing, and
distribution of algal products can help.
48
x A productive microalgal industry would include a biorefinery design, a zero-waste
production strategy, and plant incorporation and intensification, meaning each
advancement of chemical engineering, contributing to significantly reduced,
healthier, safer, and more energy-efficient technologies.
49
7. Future perspectives
Microalgae are abundant and economically important bio-resources with various
bioactive metabolites. A variety of microalgae species are yet to be studied. Such
organisms require extensive scientific research to uncover their ability to benefit
people. This will add more species to just a few existing industrial-scale microalgae. The
food, feed, health, and cosmetic industries are covered by many high-value bioactive
components from microalgae such as essential long-chain PUFAs (EPA, DHA), pigments,
single-cell proteins, and mineral derived vitamines. Sustainable development and the
growing market will likely help commercialize microalgae-based products by knowledge
and clarity on the health of the use of microalgae and regulatory issues related to
genetically engineered microalgae use. Research on the antibacterial activity of
nanosized silver colloidal solutions against human pathogens has shown strong efficacy
as a potent antimicrobial agent in the use of silver nanoparticles in drugs (Merin et al,
2010).
Additionally, multi–omics (genomics, transcriptomics, proteomics, and metabolomics)
combined with data analysis have rendered biological processes easier to understand
and require easy access to a variety of metabolic pathways for genetically modified
microorganisms. Finally, the –omics resources will create future perspectives opening
wider doors into microalgae research applications (Mishra et al, 2019).
Therefore, given the different aspects of microalgae examined, it is clear that
microalgae with a large existence around the world will satisfy the nutrition, feed, fuel
as well as human health needs. Marine microalgae provide a simple and effective route
for nanoparticle syntheses with controllable, particle-sized optical properties.
50
Bibliography
Abdo, S.M., Mona, H.H., Waleed, M.E., Rawheya, A.S.E.D., and Gamila H.A. (2012)
Antiviral activity of freshwater algae. Journal of Applied Pharmaceutical Science,
2:21–25.
Abedin, R.M.A., and Taha, H.M. (2008) Antibacterial and antifungal activity of
cyanobacteria and green microalgae, evaluation of medium components by
plackett-burman design for antimicrobial activity of Spirulina platensis. Global
Journal of Biotechnology and Biochemistry, 1:22–31.
Abel, S., Riedel, S., and Gelderblom, W.C.A. (2014) Dietary PUFA and cancer. Proceedings
of the Nutrition Society,73(3):361–367.
Adarme-Vega, T.C., Lim, D.K., Timmins, M., Vernen, F., Li, Y., Schenk, P,M. (2012)
Microalgal biofactories: a promising approach towards sustainable omega-3 fatty
acid production. Microb Cell Fact, 11:96.
Ahmadi, A., Moghadamtousi, S.Z., Abubakar, S., and Zandi, K. (2015) Antiviral potential
of algae polysaccharides isolated from marine sources: a review. BioMed Research
International, 2015:825203.
Amaro, H.M., Guedes, A.C., and Malcata, F.X. (2011) Antimicrobial activities of
microalgae: an invited review. In: Science against Microbial Pathogens:
Communicating Current Research and Technological Advances, A Mendez Vilas
(Ed.), 1272–1280.
Ambati, R.R., Gogisetty, D., Aswathanarayana, R.G., Ravi, S., Bikkina, P.N., Bo, L., and
Yuepeng, S. (2019) Industrial potential of carotenoid pigments from microalgae:
Current trends and future prospects. Crit. Rev. Food Sci.Nutr. 59, 1880–1902.
Arem, H., Neuhouser, M.L., Irwin, M.L., Cartmel B., Lu,L., Risch, H., Mayne, S.T., and Yu,
H. (2013) Omega-3 and omega-6 fatty acid intakes and endometrial cancer risk in a
population-based case-control study. European Journal of Nutrition, 52:1251–
1260.
Bae, S.Y, Yim J.H, Lee, H.K, and Pyo, S. (2006) Activation of murine peritoneal
macrophages by sulfated exopolysaccharide from marine microalga Gyrodinium
impudicum (strain KG03): involvement of the NF-kappa B and JNK pathway.
International Immunopharmacology,6 (3):473–484.
51
Bai, V.D.M, and Krishnakumar, S. (2013) Evaluation of antimicrobial metabolites from
marine microalgae Tetraselmis suecica using gas chromatography-mass
spectrometry (GC-MS) analysis. International Journal of Pharmacy and
Pharmaceutical Sciences, 5(3):17–23.
Barrow, C., and Shahidi, F. (2008) Marine nutraceuticals and functional foods. Taylor &
Francis Group: CRC Press.
Barsanti, L., and Gualtieri, P., (2019) Paramylon, a Potent Immunomodulator from WZSL
Mutant of Euglena gracilis. Molecules, 24, 3114.
Batinic, D., and Robey, F.A. (1992) The V3 region of the enveloped glycoprotein of
human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-
derived synthetic peptides. Journal of Biological Chemistry, 267:6664–6671.
Bergé J.P, Bourgougnon, N., Alban, S., Pojer, F., Chermann, J.C., Billaudel, S., Robert,
J.M., Durand, P., and Franz, G., (1999) Antiviral and anticoagulant activities of a
water soluble compound extracted from the marine diatom Haslea ostrearia.
Planta Medica, 65:604–609.
Bhagavathy, S., Sumathi, P., and Bell J.S. (2011) Green algae Chlorococcum humicola – a
new source of bioactive compounds with antimicrobial activity. Asian Pacific
Journal of Tropical Medicine, s1–s7.
Bhattacharjee, M. (2016) Pharmaceutically valuable bioactive compounds of algae.
Asian Journal of Pharmaceutical and Clinical Research, 9 (6).
Bonnet, S., Webb, E.A., Panzeca, C., Karl, D.M., Capone, D.G., and Sanudo-Wilhelmy,
S.A., (2010) Vitamin B12 excretion by cultures of the marine cyanobacteria
Crocosphaera and Synechococcus. Limnol. Oceanogr., 55 (5): 1959–1964.
Bonomini, F., Tengattini, S., Fabiano, A., Bianchi, R., and Rezzani, R. (2008)
Atherosclerosis and oxidative stress. Histol. Histopathol., 23, 381–390.
Borowitzka, M.A., Beardall, J., and Raven, J.A., (eds.) (2016) The Phusiology of
Microalgae. Developments in Applied Phycology 6, Springer International
Publishing Switzerlang.
Bougnoux, P., Hajjaji, N., Ferrasson M.N., Giraudeau, B., Couet, C., and Le Floch O.
(2009) Improving outcome of chemotherapy of metastatic breast cancer by
docosahexaenoic acid: a phase II trial. British Journal of Cancer,101(12):1978–
1985.
52
Boussiba, S. (2000) Carotenogenesis in the green alga Haematococcus pluvialis: Cellular
physiology and stress response. Physiol. Plant, 108, 111–117.
Brodie, J., and Lewis, J. (2007) Unravelling the Aglae, the Past, Present, and Future of
Algal Systematics. CRC Press, London.
Brown, G.D., Denning D.W., Gow N.A., Levitz S.M., Netea M.G., and White, T.C.(2012)
Hidden killers: human fungal infections. Science Translational Medicine, 4:1–10.
Brown, M.R. and Farmer, C.L., (1994) Riboflavin content of six species of microalgae
used in mariculture. J. Appl. Phycol., 6:61–65.
Camacho, F.G., Rodríguez J.G., Mirón A.S., García, M.C., Belarbi, E.H., Chisti, Y., and
Grima E.M. (2007) Biotech significance of toxic marine dinoflagellates.
Biotechnology Advances, 25:176–194.
Camera, E., Mastrofrancesco, A., Fabbri, C., Daubrawa, F., Picardo, M., Sies, H., and
Stahl, W. (2009) Astaxanthin, canthaxanthin and beta-carotene differently affect
UVA-induced oxidative damage and expression of oxidative stress-responsive
enzymes. Exp. Dermatol., 18, 222–231.
Carrillo-Muñoz, A.J., Finquelievich J., Tur-tur, C., Eraso, E., Jauregizar, N., and Quindós,
G., (2014) Combination antifungal therapy: a strategy for the management of
invasive fungal infections. Revista Espanola De Quimioterapia, 27(3):141–158.
Cerezuela, R., Guardiola, F.A., Meseguer, J., and Esteban, M.A. (2012) Enrichment of
gilthead seabream (Sparus aurata L.) diet with microalgae: Effects on the immune
system. Fish Physiol. Biochem., 38, 1729–1739.
Cha, K.H., Koo, S.Y., and Lee, D.U. (2008) Antiproliferative effects of carotenoids
extracted from Chlorella ellipsoidea and Chlorella vulgaris on human colon cancer
cells. Journal of Agricultural and Food Chemistry, 56:10521–10526.
Chalyk, N.E., Klochkov, V.A., Bandaletova, T.Y., Kyle, N.H., and Petyaev, I.M. (2017)
Continuous astaxanthin intake reduces oxidative stress and reverses age-related
morphological changes of residual skin surface components in middle-aged
volunteers. Nutr. Res. 48, 40–48.
Chapman, R.L., (2013) Algae: the world’s most important “plants”-an introduction.
Mitig.Adapt Strateg Glob Change, 18: 5-12.
53
Chen, C., Yeh, K., Aisyah, R., Lee, D., and Chang, J. (2011) Cultivation photobioreactor
design and harvesting of microalgae for biodiesel production: a critical review.
Bioresource Technology, 102:71–81.
Chen, X., Song, L., Wang, H., Liu, S., Yu, H., Wang, X., Li, R., Liu, T. and Li, P. (2019)
Partial Characterization, the Immune Modulation and Anticancer Activities of
Sulfated Polysaccharides from Filamentous Microalgae Tribonema sp. Molecules,
24, 322.
Cheng, J., Li, K., Yang, Z., Zhou, J., and Cen, K., (2016) Enhancing the growth rate and
astaxanthin yield of Haematococcus pluvialis by nuclear irradiation and high
concentration of carbon dioxide stress. Bioresour. Technol., 204:49–54.
Chew, B.P., Mathison, B.D., Hayek, M.G., Massimino, S., Reinhart, G.A., and Park, J.S.
(2011) Dietary astaxanthin enhances immune response in dogs. Vet. Immunol.
Immunopathol., 140, 199–206.
Chew, K.W., Yap, J.Y., Show, P.L., Suan, P.L., Juan, J.C., Ling, T. C., Lee, D.J., and Chang,
J.S., (2017) Microalgae Biorefinery: High value products perpectives. Bioresour.
Technol., 229:53-62.
Chisti, Y., 2007. Biodiesel from microalgae. Biotechnol. Adv., 25 (3):294–306.
Choi, H.D., Kim, J.H., Chang, M.J., Kyu-Youn, Y., and Shin, W.G. (2011) Effects of
astaxanthin on oxidative stress in overweight and obese adults. Phytother. Res. 25,
1813–1818.
Chrétien, F., Lortholary, O., Kansau, I., Gray, F., and Dromer, F., (2002) Pathogenesis of
cerebral Cryptococcus neoformans infection after fungemia. Journal of Infectious
Diseases, 186:522–530.
Chrétien, F., Lortholary, O., Kansau, I., Neuville, S., Gray, F., and Dromer, F.(2002)
Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia.
Journal of Infectious Diseases, 2002;186(4):522–530.
Chuang, W.C., Ho, Y.C., Liao, J.W., and Lu, F.J. (2014) Dunaliella salina Exhibits an
Antileukemic Immunity in a Mouse Model of WEHI-3 Leukemia Cells. J. Agric. Food
Chem., 62, 11479–11487.
Chuang, W.C., Ho, Y.C., Liao, J.W., and Lu, F.J. Dunaliella salina Exhibits an Antileukemic
Immunity in a Mouse Model of WEHI-3 Leukemia Cells. (2014) J. Agric. Food
Chem.,62 :11479–11487.
54
Costa, J.A.V., and De Morais, M.G., (2011) The role of biochemical engineering in the
production of biofuels from microalgae. Bioresour. Technol., 102 (1):2–9.
C-phycocyanin :a biliprotein with antioxidant, anti-inflammatory and neuroprotective
effects. Current Protein and Peptide Science, 4(3):207–216.
Custódio, L., Justo, T., Silvestre, L., Barradas, A., Duarte C.V., Pereira, H., Barreira, L.,
Rauter, A.P., Alberício, F., and Varela, J. (2012) Microalgae of different phyla
display antioxidant, metal chelating and acetylcholinesterase inhibitory activities.
Food Chemistry,131 (1):134–140. doi: 10.1016/j.foodchem.2011.08.047.
Cutignano, A., Nuzzo, G., Ianora, A., Luongo, E., Romano, G., Gallo, C., Sansone, C.,
Aprea, S., Mancini, F., D’Oro, U., and Fontana, A. (2015) Development and
Application of a Novel SPE-Method for Bioassay-Guided Fractionation of Marine
Extracts. Mar. Drugs, 13(9) :5736–5749.
Daglia, M. (2012) Polyphenols as antimicrobial agents. Current Opinion in Biotechnology,
23 (2):174–181.
Damonte, E.B., Pujol C.A.,and Coto C.E. (2004) Prospects for the therapy and prevention
of Dengue virus infections. Advances in Virus Research, 63:239–285.
Daniel, R. Antibacterial activity of the marine diatom Skeletonema costatum against
selected human pathogens. (2016) International Journal of Current
Pharmaceutical Review and Research, 7(5):233–236.
Das, B.C., Thapa, P., Karki, R., Das, S., Mahapatra, S., Liu, T.C., Torregroza, I., Wallace,
D.P., Kambhampati, S., Van Veldhuizen, P., Verma, A., Ray, S.K., and Evans, T.
Retinoic acid signaling pathways in development and diseases. Bioorg.Med.Chem.,
22, 673-683.
Davinelli, S., Nielsen, M.E., and Scapagnini, G. (2018) Astaxanthin in skin health, repair,
and disease: a comprehensive review. Nutrients,10, 522:1-12.
Depauw, F., Rogato, A., d’Alcala, M., and Falciatore, A. (2012) Exploring the molecular
basis of responses to light in marine diatoms. Journal of Experimental Botany,
vol.63:1575–1591.
Desbois, A.P., and Smith V.J. (2010) Antibacterial free fatty acids: activities, mechanisms
of action and biotechnological potential. Applied Microbiology and Biotechnology,
85(6):1629–1642.
Desbois, A.P., Mearns-Spragg, A., and Smith, V.J. (2009) A fatty acid from the diatom
55
Phaeodactylum tricornutum is antibacterial against diverse bacteria including
multi-resistant Staphylococcus aureus (MRSA). Marine Biotechnology, 11(1):45–
52.
Dewi, I.C., Falaise, C., Hellio, C., Bourgougnon, N. and Mouget J. L. (2018) Anticancer,
Antiviral, Antibacterial, and Antifungal Properties in Microalgae. In Microalgae in
Health and Disease Prevention, Levine, I.A., Fleurence J. (eds), Elsevier, London,
UK.
doi: 10.1097/MCG.0b013e3181e0b1ba
Dorgan, J.F., Sowell, A., Swanson, C.A., Potischman, N., Miller, R., Schussler, N., and
Stephenson, H.E.Jr. (1998) Relationships of serum carotenoids, retinol, alpha-
tocopherol, and selenium with breast cancer risk: results from a prospective study
in Columbia, Missouri (United States). Cancer Causes and Control, 9(1):89–97.
Dvir, I., Chayoth, R., Sod- Moriah, U., Shany, S., Nyska, A., Stark, A.H., and Madar, Z.
(2000). Soluble polysaccharide and biomass of red microalga Porphyridium sp.
alter intestinal morphology and reduce serum cholesterol in rats. British Journal of
Nutrition, 84:469–476.
Ebrahimi-Mameghani,M.E., Sadeghi, Z., Farhangi, M.A, Mehrabany, E. V., and Aliashrafi,
S. (2017) Glucose homeostasis, insulin resistance and inflammatory biomarkers in
patients with non-alcoholic fatty liver disease: Beneficial effects of
supplementation with microalgae Chlorella vulgaris: A double-blind placebo-
controlled randomized clinical trial. Clinical Nutrition,36:1001-1006.
EFSA, 2019 http://www.efsa.europa.eu/en/
El-Baz, F.K., Hussein, R.A., Saleh, D.O. and Jaleel G.A.R.A., (2019) Zeaxanthin Isolated
from Dunaliella salina Microalgae Ameliorates Age Associated Cardiac Dysfunction
in Rats through Stimulation of Retinoid Receptors. Mar. Drugs 17, 290;
doi:10.3390/md17050290
El-Baz, F.K., Jaleel, G., Saleh, D., and Hussein, R. (2018) Protective and therapeutic
potentials of Dunaliella salina on aging-associated cardiac dysfunction in rats.
Asian Pac. J. Trop. Biomed., 8, 403–410.
Enzing, C., Ploeg, M., Barbosa, M., and Sijtsma, L. (2014) Microalgae-based products for
the food and feed sector : an outlook for Europe.Vigani,M., Parisi, C., and Cerezo,
56
E. R. (eds), Joint Research Centre, Scientific and Policy Reports,
Luxembourg :Publications Office of the European Union.
EU-Pharma-legislation, 2019, https://www.export.gov/article?id=EU-Pharma-legislation
Fábregas, J., Garcia, D., Fernandez-Alonso, M., Rocha. A.I., Gomez-Puertas, P., Escribano,
J.M., Otero, A., and Coll, J.M. (1999) In vitro inhibition of the replication of
haemorrhagic septicaemia virus (VHSV) and African swine fever virus (ASFV) by
extracts from marine microalgae. Antiviral Research, 44:67–73.
Falaise, C., François, C., Travers, M.A., Morga, B., Haure, J., Tremblay, R., Turcotte, F.,
Pasetto, P., Gastineau, R., Hardivllier, Y., Leignel, V., and Mouget, J.L., (2016)
Antimicrobial compounds from eukaryotic microalgae against human pathogens
and diseases in aquaculture. Marine Drugs, 14:1–27.
Fang, W., Fa, Z., and Liao, W. (2015) Epidemiology of Cryptococcus and cryptococcosis in
China. Fungal Genetics and Biology, 78:7–15.
Fassett R.G., and Coombes J.S. (2011) Astaxanthin: A Potential Theurapeutic Agent in
Cardiovascular Disease. Marine Drugs, 9(3): 447-465.
Ferreira V.S, ConzFerreira M.E, Lima L.M.T.R, Frasés, S., de Souza, W., and Sant’Anna, C.
(2016) Green production of microalgae-based silver chloride nanoparticles with
antimicrobial activity against pathogenic bacteria. Enzyme and Microbial
Technology, 97:114–121.
Fu, W., Gudmundson, O., Puglia, G., Herjolfsson, G., Andréasson, G., Palsson, B.O., and
Brynjolfsson S. (2013) Enhancement of carotenoid biosynthesis in the green
microalga Dunaliella salina with light-emitting diodes and adaptive laboratory
evolution. Applied Microbiology and Biotechnology, 97:2395–2403.
Fujitani, N., Sakaki, S., Yamaguchi. Y., and Takenaka, H. (2001) Inhibitory effects of
microalgae on the activation of hyaluronidase. Journal of Applied Phycology,
13:489–492.
Fukui, M., Kang, K.S., Okada, K., and Zhu, B.T. (2013) EPA, an omega-3 fatty acid,
induces apoptosis in human pancreatic cancer cells: role of ROS accumulation,
caspase-8 activation, and autophagy induction. Journal of Cellular Biochemistry.,
114(1):192–203.
Galbraith, H., and Milter T.B. (1973) Effect of long chain fatty acids on bacterial
respiration and amino acid uptake. Journal of Applied Bacteriology., 36:659–675.
57
Gallardo-Rodríguez, J., Sánchez-Mirón, A., García-Camacho, F., López-Rosales L., Chisti,
Y., and Molina-Grima E. (2012) Bioactives from microalgal dinoflagellates.
Biotechnology Advances, 30:1673–1684.
García de Acilu, M., Leal, S., Caralt, B., Roca, O., Sabater, J., and Masclans, J.R. (2015)
The role of Omega-3 polyunsaturated fatty acids in the treatment of patients with
acute respiratory distress syndrome: a clinical review. Hindawi Publishing
Corporation BioMed Research International, 2015:653750.
García, P. C., Burchardt A.D., Carvalho, R.N., Gilliland, D., António, D.C, Rossi, F., and
Lettieri, T. (2014) Detection of Silver Nanoparticles inside Marine Diatom
Thalassiosira pseudonana by Electron Microscopy and Focused Ion Beam. PLoS
One.;9(5).
Garrido-Gardenas, J.A., Manzano-Agugliaro, F., Asien-Fernandez, F.G., and Molina-
Grima, E., (2018) Microalgae research worlwide. Algal Research, 35: 50-60.
Gastineau, R., Hardivillier,Y., Leignel,V., Tekaya, N., Morançais, M., Fleurence, J.,
Davidovich, N., Jacquette, B., Gaudin, P., Helio C., Bourgougnon N., and Mouget,
J.L. (2012) Greening effect on oysters and biological activities of the blue pigments
produced by the diatom Haslea karadagensis (Naviculaceae). Aquaculture,368–
369:61–67.
Gastineau, R., Pouvreau, J.B., Hellio, C., Morançais, M., Fleurence, J., Gaudin, P.,
Bourgougnon, N., and Mouget J.L. (2012) Biological activities of purified
marennine, the blue pigment responsible for the greening of oysters. Journal of
Agricultural and Food Chemistry, 60 (14):3599–3605..
Gastineau, R., Turcotte, F., Pouvreau J.B., Morançais, M., Fleurence, J., Windarto, E.,
Prasetiya, F.S., Arsad, S., Jaouen, P., Babin, M., Coiffard, L., Couteau, C., Bardeau,
J.F., Jacquette, B., Leignel, V., Hardivillier, Y., Marcotte, I., Bourgougnon, N.,
Tremblay, R., Deschênes J.S., Badawy, H., Pasetto, P., Davidovich N., Hansen, G.,
Dittmer, J., and Mouget, J.L. (2014) Marennine, promising blue pigments from a
widespread Haslea diatom species complex. Marine Drugs,12(6):3161–3189.
Gerber, P., Dutcher, J.D., Adams, E.V., and Sherman, J.H. (1958) Protective effect of
seaweed extracts for chicken embryos infected with influenza B or mumps virus.
Experimental Biology and Medicine, 99:590–593.
58
Gerecht, A., Romano, G., Ianora, A., D’Ippolito, G., Cutignano, A., and Fontana, A., (2011)
Plasticity of oxylipin metabolism among clones of the marine diatom Skeletonema
Marinoi (Bacillariophyceae). Journal of Phycology, 47:1050-1056.
Geresh, S., Adin, I., Yarmolinsky, E., and Karpasas M. (2002) Characterization of the
extracellular polysaccharide of Porphyridium sp.: molecular weight determination
and rheological properties. Carbohydrate Polymers, 50:183–189.
Geresh, S., Dubinsky, O., Arad, S.M., Christiaen, D., and Glaser, R. (1990) Structure of 3-
O-(α-D-glucopyranosyluronic acid)-L-galactopyronase, an aldobiuronic acid
isolated from polysaccharide of various unicellular red algae. Carbohydrate
Research, 208:301–305.
Geresh, S., and Malis, S.A. (1991)The extracellular polysaccharides of the red
microalgae: chemistry and rheology. Bioresource Technology, 38:195–201.
Geresh, S., Mamontov, A., and Weinstein, J. (2002) Sulfation of extracellular
polysaccharides of red microalga: preparation, characterization, properties.
Journal of Biochemical and Biophysical Methods, 50:179–187
Ghannoum, M.A., and Rice, L.B. (1999) Antifungal agents: mode of action, mechanisms
of resistance, and correlation of these mechanisms with bacterial resistance.
Clinical Microbiology Reviews,12:501–517.
Ghasemi, Y., Moradian, A., Mohagheghzadeh A, Shokravi, S., and Morowvat M.H. (2007)
Antifungal and antibacterial activity of the microalgae collected from paddy fields
of Iran: characterization of antimicrobial activity of Chroococcus dispersus.
Journal of Biological Sciences, 7(6):904–910.
Ghasemi, Y., Yazdi, M.T., Shafiee, A., Amini, M., Shokravi, S., and Zarrini G. (2004)
Parsiguine, A novel antimicrobial substance from Fischerella ambigua.
Pharmaceutical Biology, 42:318–322.
Ginsberg, R.H, Goebel, W.F, and Horsfall, F.L. (1947) Inhibition of mumps virus
multiplication by a polysaccharide. Proceedings of the Society for Experimental
Biology and Medicine, 66:99–100.
González-Delgado Á.D., Kafarov V., (2011) Microalgae based biorefinery: issues to
consider. CT&F-Ciencia, Tecnología y Futuro, 4 (4):5–22.
Griffiths, D.J., (2013) Microalgae and Man. Marine Biology. Nova Science Publiscers, NY,
USA.
59
Grimming, B., Morganti, J., Nash, K. and Bickford, P.C. (2016) Immunomodulators as
therapeutic agents in mitigating the progression of Parkinson’s disease. Brain
Science,6,41.
Guedes, A.C., Barbosa, C.R., Amaro, H.M., Pereira, C.I., and Malcata, F.X (2011)
Microalgal and cyanobacterial cell extracts for use as natural antibacterial
additives against food pathogens. International Journal of Food Science
Technology, 46:862–870.
Guerin, M. Huntley, M.E. and Olaizola, M. (2003) Haematococcus astaxanthin:
Applications for human health and nutrition. Trends Biotechnol. 21, 210–216.
Guzmán, S., Gato, A., and Calleja, J.M. (2001) Antiinflammatory, analgesic and free
radical scavenging activities of the marine microalgae Chlorella stigmatophora and
Phaeo- dactylum tricornutum. Phytotherapy Research, 15(3):224–230.
Guzmán, S., Gato, A., Lamela, M., Freire-Garabal, M., and Calleja, J.M. (2003) Anti-
inflammatory and immunomodulatory activities of polysaccharide from Chlorella
stigmatophora and Phaeodactylum tricornutum. Phytotherapy Research, 17
(6):665–670.
Harding, S.V., Zhao, H.L., Marinangeli, C.P.F., Day, A.G., Dillon, H.F., Jain, D., and Jones,
P.J.H.(2009) Red algal cellular biomass lowers circulating cholesterol
concentrations in Syrian golden hamsters consuming hypercholesterolaemic diets.
British Journal of Nutrition, 102(6):842-847.
Harris, W.S., (2014) Achieving optimal n-3 fatty acid status:the vegeterian’s
challenge…or not. American Journal of Clinical Nutrition, 1:449S-52S.
Hasui, M., Matsuda, M., Okutani, K., and Shigeta, S. (1995) In vitro antiviral activities of
sulfated polysaccharides from a marine microalga (Cochlodinium polykrikoides)
against human immunodeficiency virus and other enveloped viruses. International
Journal of Biological Macromolecules, 17:293–297.
He, K., Song, Y., Daviglus, M.L., Liu, K., Van Horn, L., Dyer, A.R, and Greenland P. (2004).
Accumulated evidence on fish consumption and coronary heart disease mortality:
a meta-analysis of cohort studies. Circulation, 109:2705–2711.
Herrero, M., Ibáñez, E., Cifuentes, A., Reglero, G., and Santoyo S. (2006). Dunaliella
salina microalga pressurized liquid extracts as potential antimicrobials. J. Food
Protein, 69: 2471–2477.
60
Hossain, Z., Kurihara, H., Hosokawa, M., and Takahashi, K. (2005) Growth inhibition and
induction of differentiation and apoptosis mediated by sodium butyrate in Caco-2
cells with algal glycolipids. In Vitro Cellular and Developmental Biology Animal,
41:154–159.
HTF Market Intelligence Consulting Pvt. Ltd. (2019) Algae Products Market Swot Analysis
by key players Cargill, Dowdupont, Kerry Group, 9 September.
https://ec.europa.eu/health/human-use/legal-framework_en
https://en.wikipedia.org/wiki/Diabetes
https://simple.wikipedia.org/wiki/Flagellum Huang, J., Chen, B., and You, W. (2005) Studies on separation of extracellular
polysaccharide from Porphyridium cruentum and its anti-HBV activity in vitro (in
Chinese). Chinese Journal of Marine Drugs, 24:18–21.
Huleihel, M., Ishanu, V., Tal, J., and Arad, S. (2001) Antiviral effect of red microalgal
polysaccharides on Herpes simplex and Varicella zoster viruses. Journal of Applied
Phycology, 13:127–134.
Huleihel, M., Ishanu, V., Tal, J., and Arad, S. (2002) Activity of Porphyridium sp.
polysaccharide against Herpes simplex viruses in vitro and in vivo. Journal of
Biochemical and Biophysical Methods, 50:189–200.
Husain, S., Wagener, M.M., and Singh, N. (2001) Cryptococcus neoformans infection in
organ transplant recipients: variables influencing clinical characteristics and
outcome. Emerging Infectious Diseases, 7:375–381.
Huseby, S., Degerlund, M., Eriksen, G. K., Ingesen, G, Ingebrigtsen, R.A., Ellertsen, H.C.,
and Hansen, E. (2013) Chemical diversity as a function of temperature in six
northern diatom species. Marine Drugs, 11:4232–4245.
Iwamoto, T., Hosoda, K., Hirano, R., Kurata, H., Matsumoto, A., Miki, W., Kamiyama, M.,
Itakura, H., Yamamoto, S., and Kondo, K. (2000) Inhibition of low-density
lipoprotein oxidation by astaxanthin. J. Atheroscler.Thromb. 7, 216–222.
Jain, Z.J., Gide, P.S., and Kankate, R.S. (2013) Biphenyls and their derivatives as
synthetically and pharmacologically important aromatic structural moieties.
Arabian Journal of Chemistry., 10:S2051–S2066 King Saud University.
61
Jorgensen, E.G. (1962) Antibiotic substances from cells and culture solutions of
unicellular algae with special reference to some chloropbyll derivatives. Plant
Physiology, 15:530–545.
Juttner, F., (2001) Liberation of 5, 8, 11, 14, 17 eicosapentaenoic acid and other polyun-
saturated fatty acids from lipids as a grazer defense reaction in epilithic diatom
biofilms. Journal of Phycology, 37:744–755.
Kagan, M.L., Sullivan, D.W., Gad, S.C., and Ballou, C.M. (2014) Safety assessment of EPA-
rich polar lipid oil produced from the microalgae Nannochloropsis oculata. Int J
Toxicol.,33(6):459-74.
Kang K.H. and Kim S.K. (2013). Beneficial effect of peptides from microalgae on
anticancer. Current Protein and Peptide Science, 14:212–217.
Kang, K.S., Wang, P., Yamabe, N., Fukui, M., Jay, T., and Zhu B.T. (2010)
Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via
reactive oxygen species formation and caspase 8 activation. PLoS One,
5(4):e10296.
Karppi, J., Rissanen, T.H., Nyyssonen, K., Kaikkonen, J., Olsson, A.G., Voutilainen, S., and
Salonen, J.T. (2007) Effects of astaxanthin supplementation on lipid peroxidation.
Int. J. Vitam. Nutr. Res. 77, 3–11.
Khoeyi, Z.A., Seyfabadi, J., and Ramezanpour, Z. (2012) Fatty acid composition of the
microalgae. Aquaculture International, 20:41–49.
Khoo, H., Sharratt, P., Das, P., Balasubramanian, R., Naraharisetti, P., and Shaik, S.,
(2011) Life cycle energy and CO2 analysis of microalgae-to-biodiesel: preliminary
results and comparisons. Bioresour. Technol., 102 (10):5800–5807.
Kim, M., Han Yim, Y., Kim, S.Y., Kim, H.S., Ghil Lee, W., Kim, S.J., Kang, S.J., Kang, P.S., and
Lee C. (2012)- inhibition of influenza A virus infection by marine microalga derived
sulfated polysaccharide p-KG03. Antiviral Research, 93:253–259.
Kishimoto, Y., Yoshida, H., and Kond, K., (2016) Potential Anti-Atherosclerotic Properties
of Astaxanthin, Marine Drugs, 14,(35):1-13.
Klaunig, J.E, and Kamendulis, L.M. (2004) The role of oxidative stress in carcinogenesis.
Annual Review of Pharmacology and Toxicology, 44:239–267.
62
Koo, S.Y., Hwang, J.H., Yang, S.H., Um, J.I., Hong, K.W., Kang, K., Pan, C.H., Hwang, K.T.
and Kim, S.M. (2019). Anti-obesity effect of standardized extract of microalgae
Phaedactylum tricornutum containg Fucoxanthin. Marine drugs, 17:311..
Kroll, H., Friedrich, J., Menzel, M., and Schreier, P. (2008) Carbon and hydrogen stable
isotope ratios of carotenoids and carotene-based dietary supplements. J. Agric.
Food Chem., 56, 4198–4204.
Kumar, S.R., Hosokawa, M., and Miyashita, K. (2013) Fucoxanthin: a marine carotenoid
exerting anti-cancer effects by affecting multiple mechanisms. Marine Drugs,
11:5130–5147.
Kurihara, H., Goto, Y., Aida, M., Hosokawa, M., and Takahashi, K. (1999) Antibacterial
activity against cariogenic bacteria and inhibition of insoluble glucan by free fatty
acids obtained from dried Gloiopeltis furcata. Fisheries Science, 65:129–132.
Kwak, J.H., Baek, S.H., Woo, Y., Han, J.K., Kim, B.G., Kim, O.Y., and Lee, J.H. (2012)
Beneficial immunostimulatory effect of short-term Chlorella supplementation:
Enhancement of natural killer cell activity and early inflammatory response
(randomized, double-blinded, placebo-controlled trial). Nutr. J., 11, 53.
Latge, J., (1999) Aspergillus fumigatus and aspergillosis. Clinical Microbiology Reviews,
12:310–350.
Lau, A.F., Siedlecki, J., Anleitner, J., Patterson, G.M., Caplan F.R, and Moore R.E. (1993)
Inhibition of reverse transcriptase activity by extracts of cultured bluegreen algae
(Cyanophyta). Planta Medica, 59:148–151
Lauritano, C., Andersen, J.H., Hansen, E., Albrigtsen, M., Escalera, L., Esposito, F.,
Helland, K., Hansen, K., Romano, G., and Ianora, A. (2016) Biocactivity screening of
microalgae for antioxidant, anti-inflammatory, anticancer, anti-diabetes and
antibacterial activities. Frontiers in Marine Science, 3:1–12
Lee, J.-B., Hayashi, K., Hirata, M., Kuroda, E., Suzuki, E., Kubo, Y., and Hayashi, T. (2006)
An sulfated polysaccharide from Navicula directa, a diatom collected from deep-
sea water in Toyama bay. Biological and Pharmaceutical Bulletin, 29:2135–2139.
Levine, I.A., and Fleurence J. (eds.), (2018.) Microalgae in health and Disease Prevention.
Elsevier, London, UK.
63
Liberman, G.N, Ochbaum, G., Malis Arad, S., and Bitton R. (2016) The sulfated
polysaccharide from a marine red microalga as a platform for the incorporation of
zinc ions. Carbohydrate Polymers,152:658–664.
Lin, K.H., Lin, K.C., Lu, W.J., Thomas, P.A., Jayakumar, T., and Sheu, J.R. (2015)
Astaxanthin, a Carotenoid, Stimulates Immune Responses by Enhancing IFN- and
IL-2 Secretion in Primary Cultured Lymphocytes in Vitro and ex Vivo. Int. J. Mol.
Sci., 17, 44.
Liu, J., Sun, Z., Gerken, H., Liu, Z., Jiang, Y., and Chen F. (2014) Chlorella zofingiensis as an
alternative microalgal producer of astaxanthin: biology and industrial potential.
Marine Drugs, 12(6):3487–3515.
López, A., Rico, M., Santana-Casiano, J.M., Gonzalez, A.G., and Gonzalez- Dávila, M.
(2015) Phenolic profile of Dunaliella tertiolecta growing under high levels of
copper and iron. Environmental Science and Pollution Research, 22(19):14820–
14828.
Lorenz, R.T. and Cysewski, G.R.(2000) Commercial potential for haematococcus
microalgae as a natural source of astaxanthin. Trends Biotechnol. 18, 160–167.
Lupescu, N., Geresh, S., Arad, S.M., Bernstein, M., and Glaser, R. (1991) Structure of
some sulfated sugars isolated after acid hydrolysis of the extracellular
polysaccharide of Porphyridium sp. unicellular red alga. Carbohydrate Research,
210:349–352.
Madhavan, J., Chandrasekharan, S., Priya, M.K., and Godavarthi, A. (2018) Modulatory
Effect of Carotenoid Supplement Constituting Lutein and Zeaxanthin (10:1) on
Anti-oxidant Enzymes and Macular Pigments Level in Rats. Pharmacog. Mag., 14,
268–274.
Majumdar, S.S., and Padiglione A.A. (2012) Nosocomial infections in the intensive care
unit. Anaesthesia and Intensive Care Medicine, 13:204–208.
Markovits A, Conejeros R, Lopez L, and Lutz M. (1992) Evaluation of marine microalga
Nannochloropsis sp. as a potential dietary supplement. Chemical, nutritional, and
short term toxicological evaluation in rats. Nutr. Res.,12:1273-1284.
Matsui, M.S., Muizzuddin, N., Arad, S., and Marenus, K. (2003) Sulfated polysaccharides
from red microalgae have antiinflammatory properties in vitro and in vivo. Applied
Biochemistry and Biotechnology, 104 (1):13–22.
64
Mendes, R.L., Fernandes, H.L., Coelho J.P., Reis, E.C, Cabral, J.M.S, Novais, J.M., and
Palavra, A.E. (1995) Supercritical CO2 extraction of carotenoids and other lipids
from chlorella vulgaris. Food Chem., 53: 99–103.
Mendiola, J.A., Santoyo, S., Cifuentes, A., Reglero, G., Ibáñez, E., and Señoráns, F.J.
(2008) Antimicrobial activity of sub-and supercritical CO2 extracts of the green
alga Dunaliella salina. Journal of Food Protection, 71 (10):2138–2143.
Merin, D.D., Prakash, S., and Bhimba, B.V. (2010) Antibacterial screening of silver
nanoparticles synthesized by marine micro algae. Asian Pacific Journal of Tropical
Medicine, 3:797–799.
Milano, J., Ong, H.C., Masjuki, H., Chong, W., Lam, M.K., Loh, P.K., and Vellayan, V.,
(2016) Microalgae biofuels as an alternative to fossil fuel for power generation.
Renewable Sustainable Energy Rev. 58, 180–197.
Mimouni, V., Ulmann, L., Haimeur, A., Guéno, F., Meskini, N. and Tremblin, G., (2015)
Marine microalgae used as food supplements and their implication in preventing
cardiovascular diseases. OCL, Oilseeds & fats Crops and Lipids. 22(4)D409.
Mishra, A., Medhi, K., Malaviya, P., and Thakur, I.S. (2019). Omics approaches for
microalgal applications: Prospects and challenges. Bioresource Technology,
291:121890.
Mizushina, Y., Hada, T., and Yoshida, H. (2012) In vivo antitumor effect of liposomes with
sialyl Lewis X including monogalactosyl diacylglycerol, a replicative DNA
polymerase inhibitor, from spinach. Oncology Reports, 28:821–828.
Mokady. S., and Sukenik, A. (1995) A marine unicellular alga in diets of pregnant and
lactating rats as a source of v3 fatty acids for the developing brain of their
progeny. J Sci Food Agric., 68:133- 139.
Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G. Benchimol,
E.I., Panaccione, R., Ghosh, S., Barkema, H.W., and Kaplan, G.G. (2012) Increasing
incidence and prevalence of the inflammatory bowel diseases with time, based on
systematic review. Gastroenterology, 142, 46–54.e42.
Montalvão, S., Demirel, Z., Devi, P., Lombardi V., Hongisto, V., Perӓlӓ, M., Hattara, J.,
Imamoglu, E., Tilvi,.S., Turan, G., Dalay, M.C., and Tammela, P. (2016) Large-scale
65
bioprospecting of cyanobacteria, micro- and macroalgae from the Aegean Sea.
New Biotechnology, 33:399–406.
Mudimu, O., Rybalka, N., Bauersachs, T., Born, J., Friedl, T., and Schulz, R. (2014)
Biotechnological screening of microalgal and cyanobacterial strains for biogas
production and antibacterial and antifungal effects. Metabolites, 4:373–393.
Mutanda, T., (2013). Introduction. In the Biotechnological Applications of Microalgae,
Faizal, B. (editor), CRC Press, Taylor & Francis Group, NY, USA.
Nagai, H., Mikami, Y., Yazawa, K., Gonoi, T., and Yasumoto T. (1993) Biological activities
of novel polyethet antifungals, gambierdic acids a and b from marine
dinoflagellate. The Journal of Antibiotics, 46:520–522.
Nagaoka, S., Shimizu, K., Kaneko, H., Shibayama, F., Morikawa, K., Kanamaru, Y., Otsuka,
A., Hirahashi, T., and Kato T. (2005) A novel protein C-phycocyanin plays a crucial
role in the hypocholesterolemic action of Spirulina platensis concentrate in rats.
Journal of Nutrition, 135:2425–2430.
Najdenski, H.M., Gigova, L.G., Iliev, I.I., Pilarski, P.S., Lukavsky, J., Tsvetkova, I.V., Ninova
M.S., and Kussovski V.K. (2013) Antibacterial and antifungal activities of selected
microalgae and cyanobacteria. International Journal of Food Science and
Technology, 48(7):1533–1540.
Nakagawa, K., Kiko, T., Miyazawa, T., Carpentero Burdeos, G., Kimura, F., Satoh, A., and
Miyazawa, T. (2011) Antioxidant effect of astaxanthin on phospholipid
peroxidation in human erythrocytes. Br. J. Nutr. 105, 1563–1571.
Nasirian, F., Sarir, H., and Moradi-kor, N., (2019). Antihyperglycemic and
antihyperlipidemic activities of Nannochloropsis oculata microalgae in
Streptozotocin-induced diabetic rats. BioMol Concepts, 10:37-43.
Nazih, H., and Bard, J.M. (2018) Microalgae in Human Health Interest as a Functional
Food. In Microalgae in Health and Disease Prevention, Levine, I.A., Fleurence j.
(eds), Elsevier, London, UK.
Nethravathy M. U., Jitendra G. Mehar, Sandeep N. Mudliar, and Ajam Y. Shekh (2019)
Recent Advances in Microalgal Bioactives for Food, Feed, and Healthcare Products:
Commercial Potential, Market Space, and Sustainability. Comprehensive Reviews in
Food Science and Food Safety, 18:1882-1897.
66
Neumann, U., Derwenskus, F., Flister, V.F., Schmid-Staiger, U., Hirht, T., and Bischoff S.C.
(2019) Fucoxanthin, a carotenoid derived from Phaeodactylum tricornutum exerts
antiproliferative and antioxidant activities in vitro. Antioxidants, 8,183.
Nobre, B.P., Villalobos, F., Barragán, B.E., Oliveira, A.C., Batista, A.P., Marques, P.A.,
Mendes, R.L., Sovová, H., Palavra, A.F., and Gouveia, L., (2013) A biorefinery from
Nannochloropsis sp. microalga – Extraction of oils and pigments. Production of
biohydrogen from the leftover biomass. Bioresour. Technol.,135:128–136.
Novartis (2019) https://www.novartis.co.uk
Novoveská, L., Ross, M.E., Stanley, M.S., Pradelles, R., Wasiolek, V. and Sassi, J.F. (2019)
Microalgal Carotenoids: a review fo production, current markets, regulations, and
future direction. Mar. Drugs, 17, 640; doi:10.3390/md17110640.
Nuno, K., Vilarruel-Lopez, A., Puebla-Perez, A.M., Romero-Velarde, E., Puebla-Mora,
A.G., and Ascencio, F. (2013) Effects of the marine microalgae Isochrysis galbana
and Nannochloropsis oculata in diabetic rats. J. Funct. Foods, 5: 106–115.
Ohta, S., Ono, F., Shiomi, Y., Nakao, T., Aozasa, O., Nakate, T., Kitamura, K., Yamaguchi,
S., Nishi, M., and Miyata H. (1998) Anti-simplex virus substances produced by the
marine green alga, Dunaliella primolecta. Journal of Applied Phycology, 10:349–
356.
Ohta, S., Shiomi, Y, Kawashima, A., Aozasa, O., Nakao, T., Nagate, T., Kitamura, K., and
Miyata, Y., (1995) Antibiotic effect of linolenic acid from Chlorococcum strain HS-
IO1 and Dunaliella primolecta on methicillin-resistant Staphylococcus aureus.
Journal of Applied Phycology, 7:121–127.
Olasehinde, T.A., Olaniran, A.O., and Okoh, A.I. (2017) Therapeutic potentials of
microalgae in the treatment of Alzheimer’s disease. Molecules,22(3) doi:
10.3390/molecules22030480.
OMS data https://www.ema.europa.eu/en/documents/presentation/oms-data-quality-
standard_en.pdf (european medicin agency science medicines health)
Paiva, S.A., Matsubara, L.S., Matsubara, B.B., Minicucci, M.F., Azevedo, P.S., Campana,
A.O., and Zornoff, L.A. (2005) Retinoic acid supplementation attenuates ventricular
remodeling after myocardial infarction in rats. J.Nutr., 135, 2326-2328.
Palozza, P., Serini, S., Maggiano, N., Tringali, G., Navarra, P., Ranelletti, F.O., and
Calviello, G. (2005) beta-Carotene downregulates the steady-state and heregulin-
67
alpha-induced COX-2 pathways in colon cancer cells. Journal of Nutrition,
135:129–136.
Palozza, P., Torelli, C., Boninsegna, A., Simone, R, Catalano, A., Mele, M.C., and Picci N.
(2009) Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus
pluvialis in human colon cancer cells. Cancer Letters, 283:108–117
Pane, G., Cacciola, G., Giacco, E., Mariottini, G.L, and Coppo, E. (2015) Assessement of
the antimicrobial activity of algae extracts on bacteria responsible of external
otitis. Marine Drugs, 13 (10):6440–6452.
Park J.S, Chew B.P, and Wong T.S. (1998) Dietary lutein from marigold extract inhibits
mammary tumor development in BALB/c mice. The Journal of Nutrition, 128
(10):1650–1656.
Park, J.H., Yeo, I.J., Han, J.H., Suh, J.W., Lee, H.P., and Hong, J.T. (2017) Anti-
inflammatory effect of Astaxanthin in phthalic anhydride-induced atopic
dermatitis animal model. Exp. Dermatol.
Park, J.S., Chyun, J.H., Kim, Y.K., Line, L.L., and Chew, B.P. (2010) Astaxanthin decreased
oxidative stress and inflammation and enhanced immune response in humans.
Nutr. Metab. (Lond.), 7, 18.
Parsaeimehr, A., Mancera-Andrade, E.I., Robledo-Padilla, F., Iqbal, H.M.N., and Parra-
Saldivar, R. (2017) A chemical approach to manipulate the algal growth, lipid
content and high-value alpha-linolenic acid for biodiesel production. Algal Res., 26:
312–322.
Pasquet, V., Morisset, P., Ihammouine, S., Chepied, A., Aumailley, L., Berard, J-B., Serive,
B., Kaas, R., Lanneluc, I., and Thiery V. (2011) Antiproliferative activity of
violaxanthin isolated from bioguided fractionation of Dunaliella tertiolect a
extracts. Maringe Drugs, 9:819-831.
Patel, V., Berthold, D., Puranik, P., and Gantar M. (2015) Screening of cyanobacteria and
microalgae for their ability to synthesize silver nanoparticles with antibacterial
activity. Biotechnology Reports, 5:112–119.
Pereira, H., Custódio, L., Rodrigues, M.J., de Sousa C.B., Oliveira, M., Barreira, L., Da Rosa
Neng, N., Nogueira J.M.F, Alrokayan S.A., Mouffouk, F., Abu-Salah, K.M., Ben-
Hamadou R., and Varela J. (2015) Biological activities and chemical composition of
68
methanolic extracts of selected autochthonous microalgae strains from the red
sea. Marine Drugs,13:3531–3549. doi: 10.3390/md13063531.
Phadwal, K., and Singh, P.K. (2003) Isolation and characterization of an indigenous
isolate of Dunaliella sp. for beta-carotene and glycerol production from a
hypersaline lake in India. J. Basic Microbiol., 43, 423–429.
Pohnert, G., (2002) Phospholipase A2 activity triggers the wound-activated chemical
defense in the diatom Thalassiosira rotula. Plant Physiology, 129:103–111.
Posten, C., and Chen, S. F. (eds), (2016) Microalgae Biotechnology. Publishing Springer
International, Switzerland.
Poudyal, H., Panchal, S.K., Diwan, V., and Brown, L. (2011) Omega-3 fatty acids and
metabolic syndrome: effects and emerging mechanisms of action. Prog. Lipid Res.
50: 372–387.
Pradhan, J., Das, S., and Das, B.K. (2014) Antibacterial activity of freshwater microalgae:
a review. African Journal of Pharmacy Pharmacology, 8(32):809–818.
Pratt, R., Daniels, T.C., Eiler, J.J., Gunnison, J.B., Kumler W.D., Oneto, J.F., Strait, L.A.,
Spoehr, H.A., Hardin, G.J., Milner, H.W., Smith, J.H., and Strain, H.H. (1944)
Chlorellin, an antibacterial substance from Chlorella. Science, 99:351–352..
Radonic, A., Thulke, S., Achenbach, J., Kurth, A., Vreeman, A., König T., Wnig T., Walter,
C., Possinger, K., and Nitsche, A. (2010) Anionic polysaccharides from phototrophic
microorganisms exhibit antiviral activities to Vaccinia virus. Journal of Antivirals
and Antiretrovirals, 2:51–55.
Rajakumar, P.D.(2018) Psychoactive Properties of Microalgae.In Microalgae in Health
and Disease Prevention, Levine, I.A., Fleurence J. (eds), Elsevier, London, UK
Ranganathan, R., and Yaakob, Z., (2013) The biology of Microalgae. In the
Biotechnological Applications of Microalgae, Faizal, B. (editor), CRC Press, Taylor &
Francis Group, NY, USA.
Raposo, M.F.J., Morais, A.M.B., and Morais R.M.S. (2014) Influence of sulphate on the
composition and antibacterial and antiviral properties of the exopolysaccharide
from Porphyridium cruentum. Life Sciences, 101:56–63.
Raposo, M.F.J., Morais, A.M.B., and Morais, R.M.S. (2015) Marine polysaccharides from
algae with potential biomedical applications. Marine Drugs, 13:2967–3028.
69
Raposo, M.F.J., Morais, A.M.B.,and Morais R.M.S. (2014) Bioactivity and applications of
polysaccharides from marine microalgae. In: Merillon J.-M, Ramawat K.G, eds.
Polysaccharides: Bioactivity and Biotechnology. Cham, Switzerland: Springer; doi:
10.1007/978-3-319-03751-6_47-1.
Raposo, M.F.J., Morais, R.M.S.,and Morais, A.M.B. (2013) Bioactivity and applications of
sulphated polysaccharides from marine microalgae. Marine Drugs, 11:233–252.
Reuter, S., Gupta, S.C., Chaturvedi, M.M., and Aggarwal, B.B. (2010) Oxidative stress,
inflammation, and cancer: How are they linked? Free Radic. Biol. Med., 49, 1603–
1616..
Riccio, G., and Lauritano, C. (2019) Microalgae with Immunomodulatory Activities. Mar.
Drugs, 18,2.
Rodriguez-Meizoso, L., Jaime, L., Santoyo, S., Senorans, F.J., Cifuentes, A., and Ibanez, E.
(2010) Subcritical water extraction and characterization of bioactive compounds
from Haematoccus pluvialis microalga. J. Pharm. Biomed. Anal. 51: 456–463.
Romay, Ch., González, R. Ledón, N., Remirez, D., and Rimbau, V. (2003)
Russo, R., Barsanti, L., Evangelista, V., Frassanito, A.M., Longo, V., Pucci, L., Penno, G.,
and Gualtieri, P. (2017) Euglena gracilis paramylon activates human lymphocytes
by upregulating pro-inflammatory factors. Food Sci. Nutr., 5:205–214.
Sanabria-Ríos D.J., Rivera-Torres, Y., Maldonado- Domínguez G., Domínguez, I., Ríos C.,
Díaz, D., Rodríguez, J.W., Altieri-Rivera, J.S., Rios-Olivares, E., Cinvares E., Cintrón,
G., Montano, N., and Carballeira, N.M. (2014) Antibacterial activity of 2-alkynoic
fatty acids against multidrug-resistant bacteria. Chemistry and Physics of Lipids,
178:84–91.
Sanmukh, S., Bruno, B., Ramakrishnan, U., Khairnar, K., Swamirnar, K., Swaminathan, S.,
and Paunikar, W. (2014) Bioactive compounds derived from microalgae showing
antimicrobial activities. Journal of Aquaculture Research and Development, 5:224.
doi: 10.4172/2155-9546.1000224.
Santocono, M., Zurria, M., Berrettini, M., Fedeli, D., and Falcioni, G. (2006) Influence of
astaxanthin, zeaxanthin and lutein on DNA damage and repair in UVA-irradiated
cells. J. Photochem. Photobiol. B, 85, 205–215.
70
Santoyo, S., Jaime, L., Plaza, M., Herrero, I., Rodriguez-Meizoso, I., Ibañez, E., and
Reglero, G. (2012) Antiviral compounds obtained from microalgae commonly used
as carotenoid sources. Journal of Applied Phycology, 24:731–741.
Santoyo, S., Plaza, M., Jaime, L., Ibañez, E., Reglero, G., and Señorans, F.J. (2010)
Pressurized liquid extraction as an alternative process to obtain antiviral agents
from the edible microalga Chlorella vulgaris. Journal of Agricultural and Food
Chemistry, 58:8522–8527.
Santoyo, S., Rodríguez—Meizoso, I., Cifuentes, A., Jaime, L., García-Blairsy Reina G., ,
Señoráns, F.J., and Ibáñez E. (2009) Processes based on the extraction with
pressurized fluids to obtain potent antimicrobials from Haematococcus pluvialis
microalgae. Lebensmittel-Wissenschaft- Food Science and Technology,
42(7):1213–1218.
Seki, T., Sueki, H., Kohno, H., Suganuma, K., and Yamashita, E. (2001) Effects of
astaxanthin from Haematococcus pluvialis on human skin. Fragr. J., 12, 98–103.
Serafini, M., Stanzione, A., Scarpa, B., and Sebastiano, F., (2010) Novel food: a new
reality in food ingredient. Journal of clinical gastroenterology, 44:47-48.
Seraspe, E.B., Ticar, B.F., Formacion, M.J., Pahila, I.G, de la Pena, M.R, and and Amar,
E.C. (2012) Antibacterial properties of the microalgae Chaetoceros calcitrans.
Asian Fisheries Science, 25:343–356.
Shankar, P.D, Shobana, S., Karuppusamy, I., Pugazhendhi, A., Ramkumar, V.S.,
Arvindnarayan, S., and Kumar G. (2016) A review on the biosynthesis of metallic
nanoparticles (gold and silver) using bio-components of microalgae: formation
mechanism and applications. Enzyme and Microbial Technology, 95:28–44
(Elsevier Inc.).
Shi, X.M., and Chen, F. (2002) High-yield production of lutein by the green microalga
Chlorella protothecoides in heterotrophic fed-batch culture. Biotechnology
Progress, 18:723–727.
Shrestha, R.P., Weinstein, Y., Bar-Zvi D., and Arad, S.M. (2004) A glycoprotein
noncovalently associated with cell-wall polysaccharide of the red microalga
Porphyridium sp. (Rhodophyta). Journal of Phycology, 40:568–580.
71
Sibi, G. (2015) Inhibition of lipase and inflammatory mediators by Chlorella lipid extracts
for antiacne treatment. Journal of Advanced Pharmaceutical Technology Research,
6(1):7–12.
Siegel, R.L., Miller, K.D., and Jemal, A. (2016) Cancer statistics, 2016. CA Cancer J. Clin.,
66, 7–30.
Sigamani, S., Ramamurthy, D., and Natarajan H. (2016) A Review on Potential
Biotechnological applications of Microalgae. Journal of Applied Pharmaceutical
Science, 6 (8):179-184.
Skulberg, O.M. (2000) Microalgae as a source of bioactive molecules – experience from
cyanophyte research. Journal of Applied Phycology, 12:341–348.
Sogawa, K., Matsuda, M., and Okutani, K. (1998) Induction of apoptosis by a marine
microalgal polysaccharide in a human leukemic cell line. Journal of Marine
Biotechnology,6(4):241–243.
Song, X.D., Zhang, J.J., Wang, M.R., Liu, W.B., Gu, X.B., Gu X. and Lv, C.J. (2011)
Astaxanthin induces mitochondria-mediated apoptosis in rat hepatocellular
carcinoma CBRH-7919cells. Biological and Pharmaceutical Bulletin, 34 (6):839–
844.
Stanier, R.Y., Kunisawa, R., Mandel, M. and Cohen-Bazire, G. (1971) Purification and
propperties of unicellular blue-green algae (order Chroococcales). Bacteriol. Rev.
35 (2):171-205.
Suganuma, K., Nakajima, H., Ohtsuki, M., and Imokawa, G. (2010) Astaxanthin
attenuates the UVA-induced up-regulation of matrix-metalloproteinase-1 and skin
fibroblast elastase in human dermal fibroblasts. J. Dermatol. Sci. 58, 136–142.
Syed, S., Arasu, A., and Ponnuswamy, I. (2015) The uses of Chlorella vulgaris as
antimicrobial agent and as a diet: the presence of bio-active compounds which
caters the vitamins, minerals in general. International Journal of Bio-Science and
Bio-Technology, 7(1):185–190.
Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., Takeda, K., and
Akira S. (1999) Differential roles of TLR2 and TLR4 in recognition of gram-negative
and gram-positive bacterial cell wall components. Immunity, 11 (4):443–451.
72
Talero, E., García-Mauriño, S., Ávila-Román, J., Rodríguez-Luna, A., Alna, A., Alcaide, A,
and Motilva, V. (2015) Bioactive compounds isolated from microalgae in chronic
inflammation and cancer. Marine Drugs, 13(10):6152–6209.
Talyshinsky, M.M., Souprun, Y.Y., and Huleihel, M.M. (2002) Anti-viral activity of red
microalgal polysaccharides against retroviruses. Cancer Cell International, 2:1–7.
Tamiaki, H., Matsunaga, S., Taira, Y., Wada, A., Kinoshita, Y., and Kunieda, M., (2014)
Synthesis of zinc 20-substituted bacteriochlorophyll-d analogs and their self-
aggregation. Tetrahedron Lett., 55 (22):3351–3354.
Tominaga, K., Hongo, N., Fujishita, M., Takahashi, Y., and Adachi, Y. (2017) Protective
effects of astaxanthin on skin deterioration. J. Clin. Biochem. Nutr. 61, 33–39.
Tominaga, K., Hongo, N., Karato, M., and Yamashita, E. Cosmetic benefits of astaxanthin
on human subjects. Acta Biochim. Pol. , 2012, 59, 43–47.
Tominaga, K., Hongo, N., Karato, M., and Yamashita, E. (2009) Cosmetic effects of
astaxanthin for all layers of skin. Food Style, 13, 25–29.
Tong, Y., and Tang J. (2017) Candida albicans infection and intestinal immunity.
Microbiological Research, 198:27–35.
Tyagi, S. (2016) Fungal pathogenicity and diseases in human – a review. Journal of
Pharmacognosy and Phytochemistry, 5:192–193.
Umemura, K., Yanase, K., Suzuki, M., Okutani, K., Yamori, T., and Andoh T.(2003)
Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer
cell lines by a marine microalgal polysaccharide. Biochemical Pharmacology,
66:481–487.
Ursoniu, S., Sahebkar, A., Serban, M.C., and Banach, M. (2015) Lipid profile and glucose
changes after supplementation with astaxanthin: A systematic review and meta-
analysis of randomized controlled trials. Arch. Med. Sci. 11, 253–266.
Vanthoor-Koopmans, M., Wijffels, R.H., Barbosa, M.J., and Eppink, M.H.M., (2013)
Biorefinery of microalgae for food and fuel. Bioresour. Technol., 135: 142–149.
Varela, J.C., Pereira, H., Vila, M., and León, R. (2015) Production of carotenoids by
microalgae: achievements and challenges. Photosynthesis Research, 125(3):423–
436.
Vidoudez, C., and Pohner, G. (2012) Comparative metabolomics of the diatom
Skeletonema marinoi in different growth phases. Metabolomics, 8:654–669.
73
Viso, A.C., Pesando, D., and Baby, C. (1987) Antibacterial and antifungal properties of
some marine diatoms in culture. Botanica Marina, 30:41–45.
Vo, T.S., Ngo, D.H., and Kim S.K. (2012) Marine algae as a potential pharmaceutical
source for anti-allergic therapeutics. Process Biochemistry, 47:386–394.
Volk, R.B., and Furkert F.H. (2006) Antialgal, antibacterial and antifungal activity of two
metabolites produced and excreted by cyanobacteria during growth.
Microbiological Research, 161:180–186.
Walter, C.S., and Mahesh, R. (2000) Antibacterial and antifungal activities of some
marine diatoms in culture. Indian Journal of Marine Sciences, 29:238–242.
Wang X. and Zhang X. (2013) Separation, antitumor activities, and encapsulation of
polypeptide from Chlorella pyrenoidosa. Biotechnology Progress, 29:681–687.
Wang, J., Wang, X.D., Zhao, X.Y., Liu, X., Dong, T., and Wu, F.A., (2015b) From microalgae
oil to produce novel structured triacylglycerols enriched with unsaturated fatty
acids. Bioresour. Technol., 184:405–414.
Washida, K., Koyama, T., Yamada, K., Kita, M., and Uemura, D. (2006) Karatungiols A and
B, two novel antimicrobial polyol compounds, from the symbiotic marine
dinoflagellate Amphidinium sp. Tetrahedron Letters, 47:2521–2525.
Willians, P.J.B., and Laurens, L.M.L. (2010) Microalgae as biodiesel and biomass feed-
stock: Review and analysis of the biochemistry, energetics and economics. Energy
and Environmental Science, 3:554-590.
Yamahita, E. (1995) Suppression of post-UVB hyperpigmentation by topical astaxanthin
from krill. Fragr. J., 14, 180–185.
Yamahita, E. (2006) The Effect of a dietary supplement containing astaxanthin on skin
condition. Carotenoid Sci., 10, 91–95.
Yeh, K.L., and Chang, J.S., (2012) Effects of cultivation conditions and media composition
on cell growth and lipid productivity of indigenous microalga Chlorella vulgaris
ESP-31. Bioresour. Technol.,105:120–127.
Yen, H.W., Hu, I.C., Chen, C.Y., Ho, S.H., Lee, D.J., and Chang, J.S., (2013) Microalgae-
based biorefinery–from biofuels to natural products. Bioresour. Technol., 135:166–
174.
74
Yim, J.H., Kim S.J., Ahn, S.H., Lee, C.K., Rhie, K.T, and Lee, H.K. (2004) Antiviral effects of
sulfated exopolysaccharide from the marine microalga Gyrodinium impudicum
strain KG03. Marine Biotechnology, 6:17–25.
Yoon, H.S., Cho, H.H., Cho, S., Lee, S.R., Shin, M.H., and Chung, J.H. (2014)
Supplementating with dietary astaxanthin combined with collagen hydrolysate
improves facial elasticity and decreases matrix metalloproteinase-1 and -12
expression: A comparative study with placebo. J. Med. Food, 17, 810–816.
Yoshida, H., Yanai, H., Ito, K., Tomono, Y., Koikeda, T., Tsukahara, H., and Tada, N. (2010)
Administration of natural astaxanthin increases serum HDl-cholesterol and
adiponectin in subjects with mild hyperlipidemia. Atherosclerosis, 209, 520–523.
You, T., and Barnett S.M. (2004) Effect of light quality on production of extracellular
polysaccharides and growth rate of Porphyridium cruentum. Biochemical
Engineering Journal, 9:251–258.
Yuan, J.P., Peng, J., Yin, K., and Wang, J.H. (2011) Potential health-promoting effects of
astaxanthin: A high-value carotenoid mostly from microalgae. Mol. Nutr. Food Res.
55, 150–165.
Zhang, X., Zhao, W.E, Hu, L., Zhao, L., and Huang J. (2011) Carotenoids inhibit
proliferation and regulate expression of peroxisome proliferators-activated
receptor gamma (PPARgamma) in K562 cancer cells. Archives of Biochemistry and
Biophysics, 512:96–106.
Zhou, Q., Zhang, P., Zhang, G., and Peng, M., (2015) Biomass and pigments production in
photosynthetic bacteria wastewater treatment: effects of photoperiod. Bioresour.
Technol., 190:196–200.
Top Related